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Abstract 
Ubiquitin Specific Protease 11 (USP11), USP4 and USP15 are highly conserved and are 
characterised by an N-terminal “domain present in ubiquitin specific proteases” (DUSP) 
and “ubiquitin-like” (UBL) domains. This DUSP-UBL (DU) domain is thought to be 
involved in substrate recognition. It was shown that USP11 co-purifies with human 
Polycomb Repressive Complex type 1 (PRC1) and regulates the stability of the E3 ligase 
component of PRC1 (Maertens et al, 2010). PRC1 repress transcription from the INK4a 
tumour suppressor locus. Hence knockdown of USP11 in primary human fibroblasts 
causes de-repression of INK4a, followed by a senescence-like proliferative arrest.  
In this project we aimed to map the interaction between USP11 and PRC1 components 
(BMI1, RING2, MEL18 and CBX8). We used two methods to investigate their 
interactions; yeast two-hybrid and in vitro pull down. Unexpectedly, we could not 
confirm a direct interaction between USP11 and any PRC1 component. We hypothesize 
that the lack of post-translation modifications, the presence of fusion tags and/or the need 
of a multi-subunit PRC1 complex might be needed to observe a high affinity interaction.  
We also aimed to map the interaction between three PRC1 components; RING2, BMI1 
and RYBP, with the ultimate aim of solving the X-ray structure of the complex. The main 
obstacle in this project was to express, extract and purify these proteins at high levels in 
bacterial culture. Preliminary data suggests that RYBP and BMI1 do not interact directly. 
Here we report the 3.6 Å resolution X-ray structure of the human USP11 DU. The 
sequence linking the DUSP and UBL domains, the DU finger, could not be assigned in the 
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electron density map due to low resolution. Comparison with the related USP4 DU crystal 
structure reveals that the structures are mostly conserved.  
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Chapter I: Introduction  
1.1 Overview of USP11  
Post-translational modifications (PTMs) play central roles in modulating the activity of 
many proteins. These modifications can occur at any time in the protein production and 
generate an active response system to regulate the cellular microenvironment. Specific 
amino acid side chains and peptide linkages are often covalently modified by enzymes 
that attach tags to proteins. PTMs can occur on its own or in combination with post-
translational cleavage through a step-wise mechanism of protein maturation or activation. 
 
1.1.1 Deubiquitinases (DUBs) 
Two PTMs, ubiquitination and deubiquitination, play a key role in different transduction 
cascades and in protein stability. Ubiquitination is a substrate specific process of 
conjugating ubiquitin (as a monomer or as polyubiquitin chains) to proteins, which is 
catalyzed by three enzymes: E1, a ubiquitin-activating enzyme; E2, a ubiquitin-
conjugation enzyme; and E3, a ubiquitin ligase that conjugates the carboxyl terminus of 
ubiquitin to a lysine residue of the target protein (Hershko et al, 1983). Various ubiquitin 
linkages are formed depending on the lysine residue involved, with different 
physiological roles. Mono- and poly-ubiquitination of Lys63-linked chains has a role in 
marking the proteins for degradation via lysosomal pathways. However other, non-
proteolytic, cell signalling pathways have also been linked to poly-ubiquitination of 
Lys63; including pathways involved in DNA damage response (reviewed in Ulrich and 
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Walden, 2010). Poly-ubiquitin chains where the linkage happens on Lys11, Lys29, or 
Lys48 are typical signals for proteasomal degradation (Ikeda and Dikic, 2008; Dammer et 
al, 2011).  
On the contrary, deubiquitination, which is the removal of ubiquitin from the target 
proteins, is done by deubiquitinases (DUBs). DUBs interact with the target ubiquitin via 
various ubiquitin-binding domains; including the zinc finger ubiquitin-specific protease 
domain, the ubiquitin-interacting motif, and the ubiquitin-associated domain. DUBs also 
contain ubiquitin-like domains (UBLs) with low sequence homology but similar tertiary 
structure to ubiquitin. These domains lack the C-terminal Gly-Gly motif and therefore 
are not cleaved off by the catalytic activity of the DUB (Komander et al, 2009).  
  DUBs have various roles in the cell (Figure 1.1). Genes encode ubiquitin (UBC, UBB, 
UBA52 and UBA80) as a linear fusion of multiple copies of ubiquitin with or without 
ribosomal proteins. DUBs generate free ubiquitin from these fusion protein chains, thus 
making ubiquitin available in the cell. In addition, DUBs can cleave ubiquitin chains from 
post-translationally modified proteins. Deubiquitination of these proteins therefore 
results in stabilization of the protein and reversal of the degradative or non-degradative 
signals. DUBs can also modify the ubiquitination level of a protein by cleaving some 
ubiquitin proteins from the chain. The process of the setting and removal of ubiquitin is 
thought to be a highly regulated process and is both substrate and ubiquitin chain type 
specific.  
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Figure 1.1 Different roles of DUBs.  
(a) DUBs cleave off single ubiquitin proteins from polyubiquitin chains. The linear fusion of 
multiple copies of ubiquitin, which are encoded by four genes; UBC, UBB, UBA52 and UBA80. 
Ubiquitin can also be found as a single protein fused with either of two ribosomal proteins, 40S 
ribosomal protein L40 (L) and 60S ribosomal protein S27a (S). (b) DUBs can prevent protein 
degradation. (c) DUBs remove a non-degradative ubiquitin signal. (d) DUBs, substrates of the 26S 
proteasome and lysosomal pathways, are involved in preserving and recycling of ubiquitin, after 
degradation of ubiquitinated proteins.  (e) DUBs add to the ubiquitin pool by generating free 
ubiquitins from polyubiquitin chains formed by en masse removal from substrates. f) DUBs are 
involved in altering ubiquitin signals by editing the ubiquitin chains attached to the substrates. 
Adapted from Komander et al, 2009. 
 
 
 
 
Degradation  
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At least 98 DUBs are encoded in the human genome. Based on their sequence and 
structural similarity, DUBs can be subdivided into six families: ovarian-tumor proteases 
(OTUs), ubiquitin-specific proteases (USPs), ubiquitin carboxy-terminal hydrolases 
(UCHs), Machado–Joseph disease protein domain proteases, JAMM/MPN domain-
associated metallopeptidases (JAMMs) and the monocyte chemotactic protein-induced 
protein (MCPIP) family (reviewed in Reyes-Turcu et al, 2009). There are over 50 USPs in 
humans, making this family the largest among DUBs.  
 
1.1.2 USPs  
USPs are large DUB proteins with a typical Mw of 100 kDa. It is thought that, unlike the 
UCH enzymes, which are 30-40 kDa in size mostly involved in the recycling of ubiquitin, 
the domains extending around the catalytic domain of USPs are involved in substrate 
recognition. All USPs have a conserved papain-like catalytic domain which upon binding 
to ubiquitin goes through conformational changes (Hu et al, 2005; Renatus et al, 2006). 
The catalytic domains combine with other domains, such as TRAF-like (Tumor necrosis 
factor Receptor-Associated Factor–like), DUSP, UBL or zinc finger, to form various USPs. 
The roles of some of these domains have been characterised. For example, in 2008, 
ubiquitin interacting motif was reported to enhance interaction with the substrate in 
USP25 (Meulmeester et al, 2008).  It has also been shown that USP8 has a microtubule-
interacting and trafficking (MIT) domain involved in localization and function of DUBs 
(Row et al, 2007).   
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Based on sequence homology, USP11 is most closely related to USP4 and USP15 
(Figure 1.2). USP4 was shown to have a role in spliceosome regulation (Song et al, 2010). 
USP15 was shown to stabilize the tumor suppressor protein adenomatous polyposis coli 
through COP9 signalosome mediated regulation (Zhou et al, 2003; Huang et al, 2009), 
regulate activity and stability of the RING-box protein Rbx1 (Hetfeld et al, 2005), caspase-
3 in Paclitaxel-induced apoptosis pathway (Xu et al, 2009) and human papillomavirus type 
16 E6 oncoprotein stability (Vos et al, 2009). Furthermore, USP15 deubiquitinates IκBα14 
resulting in down-regulation of the NF-κB pathway (Schweitzer et al, 2007).  
The “domain present in ubiquitin specific proteases” (DUSP) is thought to be involved 
in substrate recognition by USPs. Although no interaction partners are known for the 
DUSP domain of USP15, USP4 DUSP domain was shown to interact with Sart3 in the 
mRNA splicing pathway (Song et al, 2010). USP4, USP11, and USP15 contain two UBL 
domains within their sequence. The function of UBL1 domain, immediately following the 
DUSP domain is unknown. Interestingly, it was postulated that UBL2 domain in USP4 is 
involved in regulating the catalytic activity of the enzyme (Luna-Vargas et al, 2011). 
Based on this model, the UBL domain partially inhibits the deubiquitinating activity of 
the USP4 through competitive binding into the ubiquitin binding site of the catalytic 
domain (Figure 1.3). 
Harper and colleagues determined an X-ray structure of the USP15 N-terminal DUSP 
and UBL1 domains (USP11/DU) (Harper et al, 2011). They showed that these two 
domains are aligned in tandem in an 80 Ǻ elongated arrangement. The DUSP and UBL in 
USP15 are connected through an intervening β-hairpin structure (DU finger). The UBL 
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domain in USP15 is unlikely to have an ubiquitin mimicry role, even though it has a 
similar β-grasp fold to ubiquitin, because of the presence of longer loop regions and 
different surface characterisations.  
 
Figure 1.2) Schematic comparisons between USP4, USP11 and US15 domains.  
 
 
 
 
  
 
 
 
 
Figure 1.3) Schematic model of USP4 catalytic domain (D1D2) inhibition by the Ubl domain. 
D1D2, Ubl and ubiquitin (Ub) are shown in green, blue and purple, respectively. 
Adapted from Luna-Vargas et al, 2011. 
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1.1.3 USP11 
USP11 was first described as ubiquitin C-terminal hydrolase on the X chromosome 
(UHX1) (Swanson et al, 1996) and was later renamed as USP11 (Baker et al, 1999). 
TheUSP11 gene (2763 bp) encodes a 105 kDa protein which contains Cys and His boxes, 
involved in deubiquitinating activity. USP11 protein is localized mainly in the nucleus 
(Ideguchi et al. 2002). It was shown that USP11 interacts with a Ran-binding protein 
(RanBPM), involved in microtubule nucleation(Nakamura et al, 1998). 
In 2008, USP11 was identified as one of cellular targets of Human papillomaviruses 
(HPV)-16 E7 protein (Lin et al, 2008). Both USP11 and HPV-16E7 are localized in the 
nucleus and are thought to interact there. It was demonstrated that USP11 reduces the 
levels of ubiquitinated E7 and therefore decreases turnover of the viral protein. Stable E7 
regulates the downstream viral genes, and induces degradation of pRb. Conversely, Su et 
al. reported that USP11 could reduce influenza virus replication. It was showed that 
USP11 interacts with several viral RNA replication complex components; PB2, PA, and 
NP (Liao et al, 2010). These findings can potentially be used in designing antiviral drugs.    
USP11 is also thought to influence the TNFα-mediated IKKα-p53 signalling pathway. 
It was suggested that USP11 modulated levels of IKKα and may therefore be involved in 
regulating the TNFα-mediated IKKα-p53 signalling pathway (Yamaguchi et al, 2007). 
Further studies showed IκBα interacts with and is deubiquitinated by USP11. IκBα 
degradation results in TNFα-induced NF-κB nuclear translocation and activation. It was 
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proposed that the deubiquitination of IκBα is done by USP11 and USP15 that act in 
collaboration (Schweitzer et al, 2007).   
Two de-ubiquitinating enzymes, USP7 and USP11, were co-purified with Polycomb 
Repressive Complex 1 (PRC1) containing MEL18 and BMI1 from mammalian cells.  Both 
USP7 and USP11 bind to several PRC1 components forming high-molecular-weight 
complexes. USP11 was shown to remove ubiquitin from PRC1 components, MEL18, 
RING1, and BMI1, without any significant direct effect on H2A ubiquitination. 
Importantly, USP7 and USP11 were shown to regulate the stability of the E3 ligase 
subunit of PRC1 by preventing proteasomal degradation (Maertens et al, 2010).  
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1.2 Overview of Polycomb group proteins  
Polycomb group (PcG) proteins are transcriptional repressors that have a crucial role in 
regulation of epigenetic gene silencing and play a major part in embryogenesis, cellular 
differentiation and development.  Their expression or activity is often deregulated in 
cancer cells.  
 
1.2.1 PcG protein complexes  
The Polycomb group (PcG) proteins were first discovered in Drosophila melanogaster as 
repressor of homeptic (HOX) genes; proteins that affect the patterning of the male sex 
combs. It was initially shown that mutations in the PcG genes results in multiple 
homeotic transformation. The phenotype of the first mutant was disrupted segmentation 
in the form of multiple sex combs; therefore it was called Polycomb (Sandler et al, 1968). 
Further studies discovered that the Polycomb gene is part of a family, the Polycomb 
group (Lewis, 1978).  
PcG proteins form nuclear complexes which have different biochemical roles, including 
recognition and establishment of histone PTMs and chromatin compaction. They form 
chromatin-modifying complexes, called Polycomb Repressive Complex 1 and 2 (PRC1 
and PRC2, Figure 1.4), which are involved in transcriptional repression of housekeeping 
genes, through epigenetic regulation (Bracken et al, 2006). The PRC2 complex sets the 
trimethyl mark on lysine 27 of histone H3 (H3K27me3) and recruits the maintenance 
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complex PRC1, which in turn ubiquitinates Lysine 119 of histone H2A (uH2A) (Cao and 
Zhang, 2004; Cao et al, 2005; Wang et al, 2004). 
In fruit flies, PRC1 is composed of stoichiometric amounts of Polycomb (Pc), Posterior 
sex comb (Psc), Sex comb extra (Sce) and Polyhomeotic (Ph). However, the mammalian 
PcG system is considerably more complicated, as each of the PRC1 components have 
multiple orthologs: five PC proteins (CBX2/4/6/7/8), six PSC (MEL18, BMI1, MBLR, 
RNF159, NSPC1 and RNF3), three PH (HPH1, HPH2 and HPH3) and two SCE (RING1 
and RING2) (Reviewed in Gil and Peters, 2006). Of note, it is the PSC/SCE dimer 
component of PRC1 that catalyzes the ubiquitination of H2A at Lys119 (Cao et al, 2005; 
Buchwald et al, 2006).  
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Figure 1.4) The Polycomb group (PcG) proteins.  
(a)  The PRC2 complex (red) has three core components, Enhancer of Zeste (E(z)), Extra sex 
combs (Esc) and Suppressor of Zeste-12 (Su(z)12). (b) PRC2 methylates histone H3 on lysine 27 
(H3K27) catalysed by the histone methyl transferase, E(z) subunit. (c) The methylation of H3K27 
by PRC2 recruits PRC1 comprised of stoichiometric amounts of Polycomb (Pc), Posterior sex 
combs (Psc), Polyhomeotic (Ph) and Sex combs extra (Sce) proteins. (d) The chromodomain of the 
Pc protein in PRC1 recognizes the H3K27-methylated chromatin. . PRC1 ubiquitinates Lys119 of 
histone H2A. These epigenetic changes are heritable and play a major role in the establishment of 
the body pattern throughout development.Ac, acetylation; Me, methylation; P, phosphorylation. 
Adapted from Gil and Peters, 2006.   
 
The balance between silencing and activating homeotic genes is held by another group 
protein called the trithorax group (TrxG) that is shown to activate homeotic genes and 
together with the PcG proteins form the cellular memory system. In addition to PcG 
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protein, the heterogeneous group of TrxG proteins have a vital role in the epigenetic 
regulation of the cell cycle, senescence, DNA damage and stem cell biology (Reviewed in 
Schuettengruber et al, 2011). 
 
1.2.2. PRC1 components  
Polycombs: CBX8   
PC proteins are characterised by an N-terminal chromobox and a C-terminal C-box 
involved in protein-protein interaction. The chromobox domain in PC proteins was 
shown to recognize the H3K27me3 mark set by PRC2, allowing the recruitment of PRC1 
to chromatin marked for repression (Fischle et al, 2003; Min et al, 2003). Chromobox 
homolog 8 (CBX8) was first discovered in a yeast two-hybrid screen using RING1 as a 
bait. The C-box of CBX8 and the RING finger of RING1 are required for the interaction 
between the two proteins (Bardos et al, 2000).  
Although the exact significance of association is not yet clear, CBX8 is also present in 
complexes recruited by MLL fusion proteins (Monroe et al, 2011; Mueller et al, 2007) and 
essential for MLL-AF9-induced leukemogenesis (Tan et al, 2011). Myeloid/lymphoid or 
mixed-lineage leukemia (MLL) is a histone methyltransferase, involved in transcription 
activation, which plays a crucial role in early development and hematopoiesis.  
CBX8 was shown to downregulate the expression of tumour suppressor proteins, 
INK4a/ARF (Dietrich et al, 2007). Maertens and colleagues in subsequent studies showed 
that INK4a/ARF is regulated by several disctinct PRC1 complexes (Maertens et al, 2009).  
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It was suggested that PC proteins are involved in chromatin compaction (Grau et al, 
2010). It is thought that in PC-less PRC1 complexes, RYBP may substitute the role of PC 
in chromatin compaction, perhaps via its affinity to DNA (Neira et al, 2009). It is unclear 
whether CBX8 has a PRC1-independent function in transcriptional regulation, similar to 
certain other PC such as CBX4 (Kerppola, 2009).    
 
Posterior sex combs: BMI1  
PSC proteins typically contain an N-terminal RING domain followed by a largely 
unstructured region rich in proline and serine residues. The RING domain of PSC 
dimerizes with the RING domain of SCE proteins and it is this complex that functions as 
an E3 ligase to ubiquitinate H2A at Lys119 (Cao et al, 2005). Of the six described PSC 
proteins in mammals, MEL18 and BMI1 (with 71% sequence conservation) are the best 
characterised.  
B cell-specific Moloney murine leukemia virus integration site 1 (BMI1), was first 
characterised as a cooperating oncogene with the Eμ-myc transgene in B cell 
transformation in mice (van Lohuizen et al, 1991). BMI1 is a 36.8-kDa predominantly 
nuclear protein (van Lohuizen et al, 1991). Human BMI1 gene is located on chromosome 
10 (10p11.23) and encodes 326 amino acids.    
Bmi1 acts as a transcriptional repressor of the INK4a/ARF locus and therefore 
inactivates the p16INK4a-pRb and the p14ARF-MDM2-p53 pathways. Hence, Bmi1 is a 
key player in cell cycle regulation (Jacobs et al, 1999).    
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BMI1 is thought to have a crucial role in self-renewal of stem cells and has been linked to 
the initiation of cancer (Cui et al, 2007) and a number of human malignancies 
(Balasubramanian et al, 2008). Bmi1 is involved in the oncogenesis of the hematopoietic 
system (Bea et al, 2001) and small cell carcinoma in the lung (Vonlanthen et al, 2001). 
Bmi1 overexpression reactivates the human telomerase reverse trascriptase gene in 
normal fibroblasts and mammary epithelial cells (Dimri et al, 2001). Studies show that 
Bmi1 also adds a tumorigenic capacity in colon cancer (Kim et al, 2004a), 
medulloblastoma (Leung et al, 2004), laryngeal cancer (Chen et al, 2011), breast cancer 
(Kim et al, 2004b), prostate cancer (Lukacs et al, 2010), and pancreatic cancer (Proctor et 
al, 2013). Further studies have revealed that targeting BMI1 by gene therapy stops 
chemoresistance in cancer cells and therefore enhances the prognosis (Cao et al, 2011). 
 
Sex combs extra: RING1 and RING2 
RING finger protein genes were first identified in 1991 (Hanson et al, 1991), and encode 
proteins that are the core components of the mammalian Polycomb system; 
Ring1A/RING1 and Ring1B/RING2 (reviewed in Vidal, 2009). These two proteins, in 
complex with PSC, form the E3 protein ligase that catalyzes the PcG-dependent 
ubiquitylation of histone H2A. RING2 has 336 amino acids and is 100% conserved in 
human and mice.  
RING1 and RING2 share 49% amino acid sequence identity and share three conserved 
regions; the N-terminal RING finger involved in  binding PSC proteins and two 
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conserved regions at the C terminus that form a globular domain involved in 
homodimerization (Czypionka et al, 2007).   
  
Polyhomeotic  
Polyhomeotic was first described in Drosophila as two virtually identical copies, Ph 
proximal and Ph distal (Dura et al, 1985; Dura et al, 1987). Early studies identified 
evolutionary conserved functional domains in these proteins. Three mammalian PH 
proteins (850-960 aa) are homologues to, but smaller than, the Drosophila Ph proteins. 
The conserved domains in all Ph proteins are located at the C-terminus in both long and 
short splice variants; homology domain 1 (HD1), the (Cys)4-type Zn coordination- or FCS 
domain, and the homology domain II (HD2) or sterile alpha motif (SAM) domain, 
thought to be involved in protein-protein interaction.  
 
RYBP  
In 1999, a yeast two-hybrid screen for RING1A led to the identification of RING1/YY1-
binding protein (RYBP) (Garcia et al, 1999). In an effort to characterise functions of 
different mammalian PRC1 complexes large-scale proteomics was performed on distinct 
PRC1 complexes isolated from cells. It was found that RYBP (or its homolog YAF2) was 
present in most complexes, except those containing Sex combs on midleg (SCMs), PC, and 
PHs (Gao et al, 2012). SCM protein is a key transcriptional repressor of PcG. SCMs and 
PHs both contain a zinc finger motif and are related.  
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Interestingly, previous studies of PRC1 had not identified RYBP as a genuine PRC1 
component (Cao et al, 2005; Saurin et al, 2001; Maertens et al, 2009). In retrospect, 
technical factors might explain why the identification of RYBP as a PRC1 component in 
previous studies had been missed. In some of these studies epitope tags were used for PC 
proteins (Ren and Kerppola, 2011; Saurin et al, 2001), PSC (Elderkin et al, 2007; Maertens 
et al, 2009) and other PRC1 components (Cao et al, 2005; Wang et al, 2004). In other 
studies protein purifications were based on the PRC1 H2A ubiquitination activity assay 
(Wang et al, 2004).  
Gao et al reported that RYBP increases the E3 ligase activity of PSC/SCE, whilst 
Tavares et al could not discern a change in the enzymatic activity (Gao et al, 2012; 
Tavares et al, 2012). It remains to be seen what the exact role is of RYBP in the complex. 
RYBP and its homolog YAF2 were also shown to co-purify with BCOR, a complex 
involved in germinal centre formation and possibly apoptosis (Gearhart et al, 2006; 
Sanchez et al, 2007).  
 
1.2.3 The interaction between RYBP, BMI1 and RING1/2  
BMI1 and RING1/2 contain a RING finger at their N-terminal region. These proteins 
form a complex both in vivo and in vitro via their RING fingers (Satijn and Otte, 1999). 
This complex is involved in transferring the ubiquitin from the E2 to the target by 
interacting with and repositioning the E2-ubiquitin thiolester closer to the target 
(Joazeiro and Weissman, 2000). The RING finger of BMI1 plays an important part in the 
tumorigenic role of the protein (Alkema et al, 1997).  
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The structure of Ring1b/Bmi1 RING-RING complex resolution was determined at 2Ǻ 
resolution (Buchwald et al, 2006). A helix and a long loop are extended from the C-
terminus of Bmi1 and N-terminus of Ring1b RING motif, respectively (Figure 1.5). The 
RING motif has two large Zn2þ-binding loops, a short three-stranded antiparallel β-sheet, 
a central α-helix and a 310-helix. The only apparent difference between the two Ring 
motifs is the presence of three additional residues (amino acids 62 to 64) in Bmi1 
following the 310-helix.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5) Crystal structure of the Ring1b/Bmi1 RING-domain complex.  
Cartoon representation of the Ring1b and Bmi1 are shown in blue and yellow, respectively. 
Adapted from Buchwald et al, 2006. 
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Yeast two-hybrid screening showed that RYBP binds to the C-terminus of RING2 via 
its C-terminal domain (Garcia et al, 1999). Interestingly, PRC1 complexes that contain 
RYBP do not contain PC. Later studies showed that PC and RYBP bind to the same 
hydrophobic surface of RING2, despite minimal sequence identity (Wang et al, 2010) 
(Figure1.6), providing an explanation for the observation of the two distinct PRC1 type 
complexes.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6) Crystal structures of the C-terminal region  RING2 in complex RYBP/145 – 179 and 
the C-box of CBX7.  
An overlay of the two interactions is shown. RING2, CBX7 C-box and RYBP/145-179 are shown 
in black, red and green cartoon representations, respectively. Adapted from Wang et al, 2010. 
 
 
 
180o 
N 
N 
C 
C 
N 
C 
N 
C 
N
 
 N 
C 
N 
C 
31 
 
The anti-parallel β sheet in RYBP/158-172 is almost identical to the β sheet in CBX7 C-
box, and despite significant differences in the remainder of their structures, RYBP and 
CBX7 bind to the same RING2 surface (Figure 1.6). These loop structures are formed by 
the residues at the C-terminus of CBX7 C-box β sheet and at the N-terminus of RYBP β 
sheet. Therefore the conformation of the two loops is completely different (Figure 1.7). 
Intriguingly, knockdown of RYBP results in a significant drop in RING2 protein level, 
suggesting a crucial stabilizing role for RYBP on RING2 (Tavares et al, 2012).  
 
1.2.4 Functionally distinct PRC1 family complexes  
Recently, a comprehensive proteomic and genomic approach to characterise different 
mammalian PRC1 complexes was carried out (Gao et al, 2012). Using tandem affinity 
purification of PRC1 components, six distinct complexes were characterised to contain 
different members of the PSC family; PRC1.1-1.6 (Figure 1.6). Whilst it was originally 
thought that PRC1 are recruited to chromatin by the recognition of H2K27me3 by the 
chromo box region in PC, the observation that PRC1 complexes exist without PC 
proteins, suggests that distinct PRC1 subunit dependent recruitment pathways may be at 
work. RYBP was found to be part of the PRC1 complexes (PRC1.2 and PRC1.4) that do 
not contain CBXs, PHCs and SCMs. ChIP-sequence analyses suggested that PRC1 
isoforms may have different chromatin targets and biological functions (Gao et al, 2012). 
The impact of different factors in the activity of the PRC1 complexes remains to be 
determined. 
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Figure 1.7) Schematic description of PRC1 family complexes.  
Adapted from Gao et al, 2012.  
 
 
RYBP- and PC-containing versions of PRC1.4 can be reconstructed in vitro, and the 
RYBP-containing PRC1.4 has distinct stimulatory effect on the enzymatic activity of the 
RING2-BMI1. It was also shown that the knockdown of RYBP results in the failure of 
ubiquitination of H2AK119, suggesting that RYBP plays an important role in regulation 
of RING2-BMI1 activity.    
PC proteins were implicated in chromatin compaction (Grau et al, 2010). In the 
absence of PC, RYBP-PRC1 complexes may be directing the chromatin compaction, via 
the affinity of RYBP to DNA (Neira et al, 2009), although the exact mechanisms of this 
process is unknown.  
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1.2.5 Recruitment of PRC1 complexes to target loci  
The mechanism of PcG proteins recruitment to the chromatin remains enigmatic, since 
most PcG proteins do not bind DNA directly. PcG proteins interact with chromatin as 
large protein-protein complexes. In Drosophila, cis-regulatory DNA elements, dubbed 
Polycomb Response Elements (PREs) are required for PcG recruitment. These PREs are 
thought to bridge PcG complexes to target genes by DNA-protein and protein-protein 
interactions (reviewed in Muller and Kassis, 2006).  In contrast to Drosophila, mammalian 
PcG complexes have a broad distribution across the target genes they repress, making it 
difficult to identify PREs (Boyer et al, 2006; Lee et al, 2006; Ku et al, 2008).   
Association with specific DNA binding factors, binding to H3K27me3 and interactions 
with non-coding RNAs are among several models suggested for the recruitment of PRC1 
and PRC2 to their target sites (reviewed in Simon and Kingston, 2009; Schuettengruber 
and Cavalli, 2009).  Yin and Yang 1 (YY1), a ubiquitously expressed DNA binding Zn 
finger protein is known to function both as a transcriptional activator and repressor.  
Knock-down of YY1 in mouse myoblasts was shown to result in dislodgement of EZH2 
and removal of H3K27me3 from target genes (Caretti et al, 2004), suggesting a role for 
YY1 in PRC2 recruitment. It was generally accepted that PRC1 complexes are recruited 
to sites enriched with H3K27me3 by a PC protein binding this modified histone via its 
chromobox. However, the recent discovery of PRC1 complexes lacking the PC 
component (Gao et al, 2012), combined with the observation that in PRC2 null cells PcG 
target genes are still ubiquitinated at H2AK119 (Tavares et al, 2012) suggests the existence 
of alternative mechanisms of PRC1 recruitment. Indeed, the E3 ligase component of 
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PRC1 (PSC/SCE) in complex with RYBP can be detected at PcG target genes in PRC2 null 
cells (Tavares et al, 2012). It is possible that YY1 recruits the RYBP-type PRC1 complexes 
independently of PRC2, via its interaction with RYBP (Wilkinson et al, 2010), or that 
another yet undefined mechanism is at work.  
 
1.2.6 PRC1 components and regulation of p16INK4a 
In addition to genes involved in cell fate decisions and pluripotency (Bracken et al, 2007; 
Lee et al, 2006), PcG proteins were shown to regulate the INK4a-ARF-INK4b tumour 
suppressor locus (Reviewed in Gil and Peters, 2006; Sharpless, 2005).  The locus encodes 
three proteins, p16INK4a, p14ARF, and p15INK4b, which play key roles in senescence, the state 
of irreversible growth arrest in response to DNA damage and oncogenic stress.  Besides 
being a front-line defence against oncogenic mutations, senescence sets limits on 
proliferative lifespan of cells and contributes to ageing (Reviewed in Klauke et al, 2011).  
INK4a is frequently mutated, deleted or methylated in human cancers, presumably 
enabling early tumour cells to escape from oncogene-induced senescence (Ruas and 
Peters, 1998). Over-expression of PcG proteins (e.g. EZH2 in prostate and BMI1 in breast 
cancer) have a similar effect (Reviewed in Klauke et al, 2011; Schuringa and Vellenga, 
2010). This concept was demonstrated in cultured human fibroblasts, where ectopic 
expression of PRC1 components causes repression of INK4a and lifespan extension, 
whereas shRNA-mediated knockdown results in de-repression of INK4a and p16INK4a-
dependent growth arrest (Dietrich et al, 2007; Gil et al, 2004; Itahana et al, 2003; Brookes 
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et al, 2004). Maertens et al. showed that multiple variants of the PRC1 complex co-
localise on the INK4a locus and regulate its expression (Maertens et al, 2009).  
Intriguingly, shRNA-mediated knockdown of USP7 and USP11 causes de-repression of 
p16INK4a and dislodgement of PRC1 components from the locus, through the increased 
turnover of chromatin-bound MEL18 and BMI1 (Maertens et al, 2010).  
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1.3 Aims  
In 2010 Maertens et al. showed that USP11 co-localizes and interacts with PRC1 
components. It was shown that GST-USP11 can pull down CBX8, MEL18, BMI1, RING1A 
and RING1B produced in a cell-free system (Maertens et al, 2010). With the ultimate aim 
of co-crystallizing USP11 and its binding partners, I set out to investigate the interaction 
between USP11 and PRC1 components (specifically MEL18, BMI1, RING2, and CBX8) 
using yeast two hybrid and in vitro pull-down reactions. 
In 2012 RYBP was classified as a PRC1 component, which is present in the complexes 
that lack PC (Gao et al, 2012). It appears that RYBP and PC compete for the binding to 
RING2 (Wang et al, 2010). The binding between BMI1 and RING2 has been reported to 
happen through their RING domains (Buchwald et al, 2006; Li et al, 2006); it is so far not 
known whether a direct interaction exists between BMI1 and RYBP. I aimed to map the 
interaction between RING2, BMI1 and RYBP, to assist with further characterisation of 
their mechanism in the cell.  
The N-terminal region of USP11, composed of a DUSP and UBL domains, is thought to 
be involved in substrate recognition. This X-ray structure of the DUSP-UBL domain of the 
homologous USP4 and USP15 proteins was recently reported (Bacik et al, 2009; Harper et 
al, 2011). The DUSP and UBL domains are linked by a -hairpin, dubbed the DU finger. 
Whilst this USP4 fragment seems to dimerize, the homologous USP15 fragment appears to 
be monomeric. By sequence alignment, the DU finger in USP11 is shorter by three amino 
acids suggesting a different conformation of the protein in that region. In the last part of 
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this project I aimed to express and purify USP11 N-terminal domain at high levels to solve 
its X-ray structure. Further characterisation of the interaction between USP11 and the 
PRC1 components is potentially crucial in developing anti-cancer drugs that stabilize the 
PcG proteins in cancerous cells. 
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Chapter II: Materials and Methods 
2.1 DNA constructs for protein expression in bacteria   
Plasmids and oligonucleotide primers used in PCR and plasmid constructions are listed in 
Tables S1 and S2 (Appendix). All restriction enzymes were purchased from New England 
Biolabs. All plasmids generated in this work were sequence verified.  
 
2.2 DNA plasmid construction  
2.2.1 Amplification of DNA by Polymerase chain reaction (PCR) 
PCR amplifications were carried out in a GeneAmp PCR System 9700 thermocycler 
(Applied Biosystems). Template DNA (50 – 100 ng) was added to a 50 μl PCR mixture 
containing 250 μM of each deoxyribo-nucleotide triphosphate (dNTP) [deoxyribo-
adenosine triphosphate (dATP), deoxyribo-thymidine triphosphate (dTTP), deoxyribo-
cytidine triphosphate (dCTP), and deoxyribo-guanosine triphosphate (dGTP)], 100 pmol 
of each oligonucleotide primer and PfuUltra II fusion hot start DNA polymerase (1 μl) in 
1x PfuUltra II reaction buffer (Stratagene) provided with the enzyme. PCR cycling 
conditions were as follows; one cycle of denaturation at 96 °C for 5 min, 25 cycles of 
amplification consisting of denaturation for 30 sec at 96 °C, primer annealing for 30 sec at 
56 °C, followed by 1 min/kb template extension at 72 °C and ending with incubation at 72 
°C for 4 min. PCR products were separated by electrophoresis in 1% (w/v) agarose in TAE 
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buffer (40 mM Tris base, 20 mM acetic acid, 50 mM ethylenediaminetetraacetic acid 
(EDTA)) . DNA was visualized using GelRed fluorescent stain (BiotiumTM). 
 
2.2.2 DNA digestion  
DNA digestion for plasmid construction  
PCR product or plasmid DNA (5 – 10 μg) was mixed with 2 – 4 μl restriction enzyme(s) 
(40 – 80 U, New England Biolabs) in the presence of reaction buffer provided with each 
enzyme, made up to a final volume of 50 μl with double distilled water (ddH2O) and 
incubated at 37 °C for 3-5 h prior to ligation (Section 2.1.4). 
 
Analytical restriction digest  
For restriction analysis of plasmid DNA, 3 μl of plasmid (0.5-1 g) was mixed with 0.2 μl 
of each restriction enzyme (4 U) in the presence of compatible reaction buffer provided 
with the enzymes, made up to a final volume of 20 μl with ddH2O and incubated at 37 °C 
for 1 h. Digested product was analysed by electrophoresis through 1 % (w/v) agarose in 
TAE buffer.  
 
2.2.3 DNA purification from agarose gels  
DNA was extracted and purified from agarose gels using the GE Healthcare gel extraction 
kit according to the manufacturer’s instruction. Briefly, 10 μl capture buffer type 3 
(provided with kit) was added for each 10 μg agarose gel slice and incubated at 60 °C until 
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agarose was dissolved. The DNA was bound to the GFX MicroSpinTM (provided) and 
washed with 500 μl wash buffer type 1 (provided). The DNA was eluted with 30-50 μl of 
elution buffer type 4 (provided).  
 
2.2.4 DNA Ligation  
Digested and gel purified PCR and plasmid DNA fragments were mixed in a 1:1 molar 
ratio and ligated using 1 μl T4 DNA ligase (1 Weiss U, Invitrogen) in 1x ligase buffer, in a 
final reaction volume of 10 μl. The reactions were incubated at 16 °C overnight and 1 μl 
was used to transform competent Escherichia coli cells. 
 
2.2.5 Bacterial Transformation  
One μl of a ligation product or 50 ng plasmid DNA was added to 50 – 100 μl chemically 
competent DH5α strain of E. coli (Meselson and Yuan, 1968). The bacteria were incubated 
on ice for 30 min and heat shocked at 42 °C for 30 sec. The samples were cooled on ice for 
1 min, supplemented with 100 μl SOC medium (casein enzymatic hydrolysate 20 g/L, 
yeast extract 5 g/L, NaCl 0.5 g/L, MgSO4 2.4 g/L, KCl 0.186 g/L and 0.4% glucose) and 
incubated at 37 °C for 1 h. The cells were plated onto selective Luira Bertani broth (LB) 
agar plates supplemented with appropriate antibiotics and incubated overnight at 37 °C to 
allow formation of colonies.  
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To isolate plasmid DNA, single colonies were picked to inoculate 5 ml LB cultures 
supplemented with antibiotics for selection. The cultures were grown overnight at 37 °C 
and plasmid DNA was purified by small-scale (mini) preparation (Section 2.2.7).   
 
2.2.6 Screening bacterial clones for the intended plasmid constructs by colony PCR 
Bacterial colonies were screened directly for the presence of the desired insert by colony 
PCR. In some cases, purified plasmid DNA was analysed by restriction digestion in order 
to determine if the desired insert was present (Section 2.2.2). 
Ten to twelve bacterial colonies were selected from the culture plate. Each was added 
to a 20 μl PCR mixture containing 125 μM of each dNTP, 10 pmol of each oligonucleotide 
primer (one that anneals to the insert and one that anneals to the vector), 0.5 U Taq DNA 
polymerase (Invitrogen) and 2 mM MgCl2 made up in 1x PCR buffer provided with the 
enzyme. Ligation product (0.5 μl) was used as a positive control. A clear area on the 
culture plate was used as negative control. PCR cycling conditions were as follows; 5  min 
incubation at 96°C, 35 cycles consisting of denaturation for 30 sec at 96 °C, primer 
annealing for 30 sec at 52 °C followed by 1 min template extension at 72°C and ending 
with incubation at 72 °C for 7 min. The products were separated by electrophoresis in 1% 
agarose. 
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2.2.7 Small scale preparation of plasmid DNA (miniprep)  
A single bacterial colony was used to inoculate 5 ml LB supplemented with the 
appropriate antibiotics and grown overnight in a shaking incubator at 37°C. Plasmid DNA 
was purified from the bacterial pellet using miniprep kits (Fermentas). Briefly, bacterial 
pellet was resuspended in 250 μl of the Resuspension Solution (provided with the kit). To 
lyse cells 250 μl of Lysing Solution (provided) was added and mixed gently. To neutralize 
the bacterial lysate, 350 μl of the Neutralization Solution was added and mixed gently. 
The lysate cleared from the debris by centrifugation at 10,000 g was bound to the 
GeneJET spin column (provided) to capture the DNA plasmid and washed twice with 500 
μl of the wash solution (provided) before eluting with 30-50 μl of the elution buffer 
(provided).  
 
2.2.8 Medium scale preparation of plasmid DNA (midiprep) 
A single bacterial colony was used to inoculate a starter culture in 5 ml LB medium, 
supplemented with appropriate antibiotics for 8 h. The starter culture was used to 
inoculate a larger-scale bacteria culture in 150 ml selective LB medium at 37 °C over-night 
with vigorous shaking.  The cells were harvested and plasmid DNA was purified from the 
pellet using the Qiagen HiSpeed Midiprep kit. Briefly, the bacterial pellet was 
resuspended in 6 ml Buffer P1 (provided) and lysed by addition of 6 ml lysis buffer P2 
(provided). The suspension was mixed and incubated for 5 min at room temperature. To 
neutralize sodium hydrozide present in the lysing buffer, 6 ml of chilled buffer P3 
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(provided) was added, the suspension was mixed, transferred to a cartridge (provided) and 
incubated for 15 min. The lysate was cleared from debris by filtering the suspension 
through a cartridge (provided). The DNA was allowed to bind to equilibrated QIAGEN-tip 
(provided) by gravity flow. The column was washed with 20 ml of buffer QC (provided) 
and DNA was eluted with 5 ml of buffer QF (provided). DNA was precipitated by adding 
3.5 ml isopropanol and the sample was centrifuged for 30 min at 17,000 g at 4 °C. The 
supernatant was removed and the DNA pellet was washed with 2 ml ice cold 70% 
ethanol. The DNA pellet was air dried for 5-10 min and dissolved in TE buffer (provided). 
 
2.2.9 Preparation of chemically competent E. coli  
Chemically competent E. coli were prepared using published procedures (Inoue et al, 
1990). Briefly, bacteria were grown in LB medium at 18 °C until OD600 absorbance reached 
0.8. The culture was cooled down on ice for 10 min, before harvesting the cells by 
centrifugation at 18,000 g for 1 min. The bacterial pellet was gently resuspended in 30 ml 
ice-cold transformation (TB) buffer (10 mM piperazine-N,N’-bis-2-ethanesulfonic acid 
(PIPES) pH 6.7, 15 mM CaCl2, 250 mM KCl and 55 mM MnCl2). Resuspended cells were 
incubated on ice for 10 min. Cells were harvested again and resuspended in 8 ml TB buffer 
supplemented with 7% dimethyl sufoxide (DMSO). The cells were incubated on ice for 
further 10 min, aliquoted and snap-frozen by immersion into liquid nitrogen.  
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2.2.10 Site-directed mutagenesis 
The pCDF-DUET1-USP11/76-286 plasmid was used as a template to obtain three sets of 
amino acid substitutions in the DU domain of USP11; [E106A/K107A], [K146A/E147A] 
and [K278A/K279A]. Mutations were introduced by site directed mutagenesis. Fifty ng 
template plasmid was amplified for 18 cycles after denaturing at 96°C for 2 min. In each 
cycle the primers were annealed for 1 min at 58 °C and extended for 5 min at 72 oC. The 
mixture was incubated for further 10 min at 72 °C and cooled to below 37 oC. One μl DpnI 
(New England BioLabs) was added to the mixture and incubated for 1 h at 37 oC. One μl of 
DpnI-treated DNA was used to transform competent E. coli. The plasmids containing the 
correct mutation, verified by sequencing were used for protein expression.  
 
2.3 Yeast two-hybrid assay 
2.3.1 MATCHMAKER GAL4 Two-Hybrid System 3 
Yeast AH109 was transformed with pGADT7 and pGBKT7 by the lithium acetate-
mediated method (CLONTECH). Briefly, for small scale transformation of yeast cells, 
competent cells were prepared by inoculating   50 ml YPDA medium with 2-3 yeast 
colonies and incubating them at 30 °C for 16-18 h, with vigorous shaking. When OD600 of 
the culture reached 2, 5 ml of the culture was used to inoculate 300 ml YPDA and 
incubated at 30 °C for 3 h, with vigorous shaking. After harvesting the cells by 
centrifugation, the cell pellet was washed in 30 ml TE (10x TE buffer: 0.1 M Tris-HCl pH 
7.5, 10 mM EDTA) and then resuspended in 1.5 ml of TE buffer supplemented with 0.1 
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mM lithium acetate. The competent cells were transformed by adding the mixture of 
DNA-BD/Bait plasmid (0.5 μg), AD/pray plasmid (0.1 μg) and herring testis carrier DNA 
(10 μg) to 100 μl of yeast competent cells. The mixture was supplemented with 0.6 ml 
PEG/LiAc solution and mixed by vortexing. The cells were incubated at 30 °C for 30 min 
with vigorous shaking. Seventy μl DMSO was added to the culture and gently mixed. The 
cells were incubated at 42 °C for 15 min, then cooled down on ice for 2 min and plated on 
selective minimal YPDA agar plates.       
To select for yeast cells co-transformed with both plasmids, the yeast cells were grown 
on double drop-out plates (minimal medium missing Leu and Trp), and incubated at 30 °C 
for 7 days. Four colonies from each transformation were then streaked out onto quadruple 
drop-out plates (minimal medium missing Leu, Trp, His and Ade) to check for expression 
of the reporter genes and incubated at 30 °C. Colonies were allowed to form for 7 days 
before analysis. 
 
2.3.2 Yeast Protein Extraction 
Five ml YPDA medium was inoculated with a fresh yeast colony, co-transformed with 
pGBKT7 and pGADT7-USP11. Untransformed AH109 was used as negative control. The 
overnight grown pre-culture was used to inoculate 50 ml YPDA medium. Cultures were 
incubated at 30 °C with vigorous shaking until the OD600 reached 0.5. The cultures were 
cooled down by pouring them into a 100-ml tube, half-filled with ice. Cells were 
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harvested by centrifugation and washed with ice-cold ddH2O. The pellet was then snap-
frozen in liquid nitrogen and stored at -80 °C.  
Cells were thawed by resuspending the pellet in 1 ml pre-warmed cracking buffer (8 M 
Urea, 5% (w/v) SDS, 40 mM Tris pH 6.8, 0.1 EDTA, 0.4 mg/ml Bromophenol blue) 
supplemented with 10 μl β-mercaptoethanol, 20 μl protease inhibitor solution and 50 μl 
PMSF. Glass beads were added to the samples which were heated at 70 °C for 10 min and 
vortexed for 1 min. The lysate was cleared from debris, boiled for 3 min, and vortexed for 
1 min. The resulting lysates were boiled in SDS-PAGE loading buffer for 2 min and 
proteins were separated by Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE) electrophoresis. The proteins were detected by Western blotting (section 
2.5.3).  
 
2.4 Recombinant protein expression and purification 
All, except the first, column purification steps were carried out using an ᾹKTA Purifier 
HPLC instrument (GE Healthcare). 
 
2.4.1 Recombinant protein expression  
The recombinant expression plasmid coding for GST- or hexahistidine (His6-) tagged 
proteins was transformed into the PC2 [BL21(DE3)ΔendA::TcR, pLysS] or Rosetta-
2(DE3)pLacI (Novagen) E. coli cells. A colony was used to inoculate LB or Terrific Broth 
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(TB) medium, supplemented with appropriate antibiotics. The culture was grown to an 
OD600 of 0.9 in LB selective medium, or 2 in TB selective medium, and induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at 25 °C for 4 h or at 18 °C for 16-20 h. The 
bacteria were then harvested by centrifugation at 28,000 g 4 °C and stored at -80 °C until 
use. 
 
2.4.2 Affinity purification of GST-tagged recombinant proteins  
Proteins required specific extraction conditions. In this section the general purification 
steps are described. The complete buffer composition is given for each protein in the 
relevant results chapter.  Cells were harvested and lysed in ice-cold buffer A (25 mM Tris–
HCl, pH 7.4, different NaCl concentrations) plus 1 mM phenylmethylsulfonyl fluoride 
(PMSF). Where the Rosetta2(DE3)pLacI strain was used, hen egg white lysozyme was 
added to aid bacteria lysis. Since the PC2 strain expresses lysozyme, addition of lysozyme 
was not required when extracting proteins from PC2 cells. Before sonicating the cells on 
ice, 1% Triton X-100 was added to the resuspended cells. Cell debris was removed from 
the sonicated samples by centrifugation at 16,000 g for 30 min at 4oC. The samples were 
bound to a column of pre-equilibrated Glutathione Sepharose resin (GE Healthcare) in 
buffer A. The column was washed with 100ml of buffer A, proteins eluted in buffer A 
with 20 mM glutathione (pH 7.8) in 1-ml, or 0.5-ml fractions. Fractions enriched with 
recombinant proteins were identified by SDS PAGE and pooled.  
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In some cases, the GST-tag was cleaved overnight at 4 °C by incubation with human 
rhinovirus 14 3C protease (ratio of GST-tagged protein to protease was kept at 50:1 (w/w)) 
in the presence of 5 mM DTT. The NaCl concentration of the protein was reduced by 
diluting the protein with 25 mM Tris pH 7.4 and run over an anionic/cationic exchange 
column (GE Healthcare). Each protein was eluted with a unique linear salt gradient from 
the ion exchange column. Fractions enriched in recombinant proteins were pooled. 
Purified proteins were concentrated to the appropriate level and supplemented with 2 
mM DTT and 10% glycerol, snap frozen in liquid nitrogen and stored at -80 °C. 
 
2.4.3 Affinity purification of His6-tagged recombinant proteins  
Bacterial pellets were resuspended in ice-cold buffer A (25 mM Tris–HCl pH 7.4, different 
NaCl concentrations) plus 1mM PMSF and sonicated on ice. Cell debris was removed from 
the sonicated samples by centrifugation at 16,000 g for 30 min at 4 oC. The samples were 
bound to a column of pre-equilibrated CL-Nickel ChroMatrix resin (Jena Bioscience) in 
the presence of 10 mM imidazole. The column was washed with 100ml buffer A 
supplemented with 10 mM imidazole, and proteins were eluted in buffer A with 200 mM 
imidazole in 1-ml fractions. Fractions containing recombinant protein were pooled. In 
some cases, the His6-tag was cleaved overnight at 4 °C by incubating with human 
rhinovirus 14 3C protease (ratio of His6-tagged protein to protease was kept at 50:1 (w/w)) 
in the presence of 5 mM DL-Dithiothreitol (DTT). For His6-SUMO tagged proteins, the 
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His6-SUMO tag was removed by addition of His6-Ulp1 (provided by Dr. G Maertens) in 
the presence of 5 mM DTT. Protease cleavage was done overnight at 4°C.  
 
2.4.4 Ion exchange and size exclusion chromatography 
The salt concentration of the protein eluted from the glutathione sepharose or CL-Nickel 
ChroMatrix, was reduced by diluting the samples with ice cold 25 mM Tris pH 7.4. 
Proteins were bound to 5-ml HiTrap Q (anion-exchange) or SP (cation exchange) columns 
(GE Healthcare). Recombinant protein was eluted with a linear 50-500 mM NaCl gradient 
in 25 mM Tris-HCl, pH 7.4. Fractions enriched with recombinant protein were pooled. If 
necessary, further purification was carried out by size exclusion chromatography on a 
HiLoad 16/60 Superdex-200 column (GE Healthcare). Purified proteins were concentrated 
to the appropriate level, supplemented with 2 mM DTT and 10% glycerol and snap-frozen 
in liquid nitrogen and stored at -80 °C. 
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2.5 Protein Analyses  
2.5.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
To fractionate protein samples, polyacrylamide gel electrophoresis was used.  An 11% 
resolving gel comprises monomer mix (11% acrylamide, 0.29% bisacrylamide, 0.1% (w/v) 
sodium dodecyl sulphate (SDS) and 0.38 M Tris-HCl, pH 8.8) supplemented with 0.042% 
(w/v) ammonium persulphate and 0.084% (v/v) N,N,N’,N’-Tetramethylethylenediamine 
(TEMED). An 11% resolving gel was topped with 4% stacking gel, containing a monomer 
mix (4% acrylamide, 0.1% bisacrylamide, 0.1% (w/v) SDS and 0.12 M Tris-HCl, pH 6.8) 
supplemented with 0.046% (w/v) ammonium persulphate and 0.123% (v/v) TEMED.  
Protein samples were mixed with Laemmli sample buffer (4x Stock: 8% (w/v) SDS, 40% 
(v/v) glycerol, 0.01% bromophenol blue, 250 mM Tris-HCl, pH 6.8 supplemented with 25 
mM DTT). The proteins were separated by SDS-PAGE (11% gel) run at 180 V in Tris-
Glycine-SDS (TGS) buffer (25 mM Tris, 250 mM glycine, 0.1% (w/v) SDS) (Laemmli, 
1970).  
 
2.5.2 Staining PAGE gels with Coomassie dye 
In order to visualise the separated proteins by SDS-PAGE, Coomassie Brilliant Blue R250 
was used. Gels were soaked and agitated in Coomassie solution (40% (v/v) methanol, 10% 
(v/v) acetic acid, 0.1% (w/v) Coomassie R250) for more than 2 h. In order to obtain a clear 
background, the staining solution was replaced with destaining solution (40% (v/v) 
methanol, 5% (v/v) acetic acid). 
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2.5.3 Western blotting 
To electrotransfer proteins to nitrocellulose membrane (Bio-Rad), the SDS-PAGE gel was 
blotted at 100 V for 1 h in transfer buffer (25 mM Tris, 192 mM glycine). The membrane 
was blocked in phosphate buffered saline (PBS) supplemented with 5% (v/v) skimmed 
milk (Marvel) for 30 min at room temperature with gentle agitation. Primary antibodies 
(Table 2.1) were diluted in 5% milk/PBST (PBS supplemented with 0.1% Tween-20) and 
allowed to bind to the membrane for 1 h at room temperature. The membrane was 
washed with three changes of PBST allowing 10 min for each wash and incubated for 1 h 
with horse radish peroxidase (HRP)-conjugated secondary antibodies diluted in PBST. 
After 3-5 washes in PBST, signals were developed using ECL-plus chemiluminescent 
detection reagents (Pierce).  
 
Antibodies used for Western blotting 
Antibodies used in this study are listed in Table 2.1. 
Primary Antibody Secondary Antibody 
Anti-USP11 (1:2000)  
(Maertens et al, 2009) 
Anti-Rabbit IgG (1:2000)  
(GE Healthcare) 
Anti-mRing1b (1:500)  
(Kindly provided by H. Koseki, RIKEN 
Institute, Japan)  
Anti-Mouse IgG (1:2000) 
(GE Healthcare) 
Anti-His6 (1:1000)  
(Qiagen) 
Anti-Mouse IgG (1:2000)  
(GE Healthcare)  
HRP conjugated M2 Anti-FLAG (1:2000) 
(Sigma) 
___ 
Table 2.1) Antibodies used in this study. 
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2.6 In vitro pull down assays 
2.6.1 Glutathione-S-transferase pull down assays 
The GST-tagged proteins or GST (used as a negative control) were incubated with the 
desired protein (typically 5 μg each) and 15 μl glutathione sepharose beads (settled bead 
volume) (Sigma) in 1 ml binding buffer (0.15 M NaCl, 2 mM DTT, 0.02 M Tris pH 7.4, 
0.5% NP40, 1 mM PMSF) for 3 h at 4 °C with gentle agitation. Ten μg of bovine serum 
albumin (BSA, Sigma) was added to reduce non-specific binding. After extensive washes 
with binding buffer, the bound proteins were eluted by boiling the beads in 30 μl 3x 
Laemmli buffer. Ten μl was separated on an 11% SDS-PAGE gel. Proteins were visualized 
by Coomassie staining (Section 2.5.2).  
 
2.6.2 His6-tag pull down assays 
An aliquot of 10-15 μl of CL-Nickel ChroMatrix (settled bead volume) was washed with 
binding buffer (25 mM Tris pH 7.4, 150 mM NaCl, 0.1% NP40, 1 mM DTT, 10% glycerol 
and 20 mM imidazole). One ml binding buffer was added to the CL-Nickel ChroMatrix 
beads as well as 5 μg of either of the His6-tagged proteins and 10 μg BSA. For the negative 
control, no His6-tagged protein fragments were added to the beads. The samples were 
incubated with the desired protein (5 μg) for 3 h at 4 °C, with gentle rocking. The beads 
were washed extensively with the binding buffer to remove unbound proteins. Thirty μl 
3x Laemmli sample buffer was added to the beads and bound proteins were eluted by 
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boiling the beads for 3 min. Ten μl was fractionated on 11% SDS-PAGE gel. Proteins were 
visualized by Coomassie staining (section 2.5.2). 
 
2.7 Crystallization and structure determination 
Purified USP11/76-286 at a concentration of 20 mg/ml was used to set up crystallization 
trays where equal amounts of USP11/76-286 and precipitant solution were mixed. 
Initially, sitting drop crystallization screening was done in MRC 96-well crystallization 
plates (Molecular Dimensions) using several commercial sparse matrix screens; including 
Crystal screen 1 and 2, PEG/Ion, Index, (Hampton Research), Structure screen I and II, 
Morpheus, JCSG-plus, PACT premier, ProPlex, Midas, (Molecular Dimensions), Wizard 
screen I and II, Wizard Cryo I and II, JBScreen Cryo (Jena Biosciences). In each well, 0.2 
l protein and 0.2 l precipitant were mixed using the Mosquito robot, and the plates 
were incubated at 18 °C in a vibration-free incubator. Formation of precipitates and 
crystals was examined regularly using a stereo microscope (Leica).  
For optimizing the crystallization conditions, hanging drop vapour diffusion 
crystallization experiments were setup in greased 24- and 48-well plates (Hampton 
Research) by mixing 1 μl of protein-DNA complex solution with 1 μl reservoir solution on 
a siliconized cover slip (Hampton Research). Crystallization was allowed to occur at 18 °C 
in a vibration-free incubator.  
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Intact crystals were dipped into cryoprotectant, using appropriate sized cryoloops 
(Hampton Research) and snap-frozen by immersion into liquid nitrogen. The crystals 
were stored in liquid nitrogen until the diffraction experiments were carried out. X-ray 
diffraction data, collected at beam line I03 of the Diamond Light Source (Oxfordshire, UK) 
at 100K, were integrated with XDS (Kabsch, 2010), merged and scaled using Scala CCP4 
(Collaborative Computational Project, number 4, 1994) of the CCP4 suite. Crystals 
diffracted to 3.6-Ǻ resolution.  
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Chapter III: Mapping the interaction between PRC1 components 
and USP11  
Maertens et al. described the presence of USP11 in PRC1 complexes purified from human 
cells (Maertens et al, 2010). In an attempt to characterise further the interaction between 
USP11 and PRC1 components, we used several in vitro approaches, as described below.  
 
3.1 Results  
Several plasmids were constructed to express different PRC1 and USP11 protein 
fragments in bacteria and yeast to investigate the interaction (Table 3.1).   
 
 
 
 
 
 
 
Table 3.1) Plasmid constructs made to express different fragments of USP11 and PRC1 
components. 
Plasmids   
(yeast two-hybrid screens) 
Plasmids  
(in vitro pull downs)  
pGADT7M-USP11/ΔDUSP pGEX-6p-3-BMI1 
pGADT7M-USP11/ΔDUSP 
ΔDUF 
pGEX-6p-3- BMI1/1-109 
pGAT7M-USP11/ΔUCH1 pGEX-6p-3-RING1B/1-331 
pGADT7M-USP11/ΔUCH2 pGEX-6p-3-RING1B/1-159 
pGADT7M-
USP11/ΔUCH1&UCH2 
pCDF-H6P-Duet1-USP11/76-286 
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3.1.1 Investigating the interaction by Yeast Two-Hybrid assay 
In order to identify the minimal binding regions involved in a direct interaction between 
USP11 and PRC1 components a yeast two-hybrid assay was used to avoid the need to 
purify many different USP11 and PRC1 deletion mutants.  A direct interaction between 
different PRC1 core components using yeast two-hybrid had previously been established 
in AH109 yeast cells (Maertens G., unpublished results).  
Constructs were cloned to produce USP11 fused to the activation domain (AD), and 
selected PRC1 protein components (MEL18-Flag, MEL18/ΔRING-Flag (residues 121-344), 
MEL18/RING-Flag (residues 1-121) and BMI1-Flag) fused to the DNA binding domain 
(DB). Plasmids expressing DB-p53 and AD-SV40 large T antigen (LTAg) were co-
transformed into yeast AH109 as a positive control, and DB-Lamin C and AD-SV40 LTAg 
as negative control.  
In order to eliminate the possibility of detecting false positive results (by activation of 
the reported genes), plasmids containing either DB-MEL18 or -BMI1 fusion genes were 
co-transformed with a plasmid expressing only the AD. Likewise, AD-USP11 was co-
expressed with a plasmid expressing only the DB domain in yeast.  
Only yeast cells which were co-transformed with plasmids containing DB-p53 and AD-
LTAg formed colonies on the selection media (Table 3.1).  This confirmed that the yeast 
two-hybrid system is efficient. 
AH109 cells were then transformed to express AD-USP11 together with DB fused 
MEL18-Flag, MEL18/ΔRING-Flag, MEL18/RING-Flag or BMI1-Flag. Unexpectedly, no 
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yeast colonies formed on the selective medium and therefore no interaction could be 
confirmed (Table 3.2). Expression of the MEL18- and BMI1-Flag deletion constructs in 
the yeast cells was previously confirmed by Dr. G. Maertens (unpublished results). 
To ensure that USP11 is expressed in the yeast cells Western blot was carried out on 
the yeast extracts (Figure 3.1). Based on these results the expression level of USP11 was 
determined to be low.  
 
 
 
 
 
 
 
 
 
 
Table3.2) Yeast two-hybrid assay results.  
Proteins used in the yeast two-hybrid, either fused with DNA binding domain or 
activating domain are shown here. (+) indicates that colonies were formed on the 
selection medium after 7 days incubation, and (-) shows the absence of colonies.  
 
 
 
 
 
 
Bait-DB Prey-AD Colony formation 
P53                  LTAg + 
Lamin C LTAg - 
MEL18-Flag ___ - 
MEL18/ΔRING-Flag ___ - 
MEL18/RING-Flag ___ - 
BMI1 - Flag ___ - 
___ USP11 - 
MEL18-Flag USP11 - 
MEL18/ΔRING-Flag USP11 - 
MEL18/RING-Flag USP11 - 
BMI1 - Flag USP11 - 
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Figure 4.1) Western blot of yeast extracts shows low expression of USP11.  
In each lane, 10 μl of yeast extract was applied to the 11% SDS-PAGE gel.  
 
 
 
3.1.2 Investigating the interaction between USP11 and PRC1 by in vitro pull down 
assays 
3.1.2.1 Large scale expression and purification of proteins  
Full length CBX8-FLAG, His6-SUMO-tagged USP11/76-963, and His6-tagged USP11/306-
963 were kindly provided by Dr. G. Maertens. His6-tagged USP11/76-286 was expressed 
and purified as described in Chapter III. Baculovirus-produced FLAG-mBmi1 and FLAG-
mRing1b were kindly provided by Dr. Sarah Elderkin (Babraham Institute, Cambridge).  
Constructs were cloned to express GST-tagged BMI1, BMI1/1-109 (RING domain), 
RING2/1-331 and RING2/1-159 (Buchwald et al. 2006).  PC2 cells were transformed with 
each of these plasmids and two litres of LB medium was used to grow the bacterial culture 
to OD600 of 0.8. At this stage the bacteria were induced to express the desired protein at 25 
           Mw      (-)          pGADT7- 
    USP11 
USP11 
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°C for 4 h. The cells were harvested and after clearing the sonicated lysate from debris, the 
GST-tagged proteins were purified over a Glutathione Sepharose resin (Figure 3.2). A 
fraction of resin-bound proteins was used to pull down USP11 fragments (Figure 3.4).  
Purification of untagged-RING2/1-331 is described in Chapter V, section 5.1.1.  
 
 
 
 
 
 
 
Figure 3.2) Extraction, purification and binding of GST-tagged BMI1/1-109, RING2/1-331 and 
RING2/1-159. 
Samples from sonicated (Son.) lysate, supernatant (Sn.) of cleared lysate were separated by PAGE. 
Samples from the glutathione sepharose resins bound proteins were also examined to confirm the 
presence of purified GST-tagged proteins (Prot.). The arrows show migration of GST-tagged 
BMI1/1-109, RING2/1-331 and RING2/1-159, from left to right respectively.    
.  
 
 
 
3.1.2.2 In vitro Pull Down assays 
Glutathione sepharose to which GST-tagged BMI1/RING, RING2/1-331 or RING2/1-159 
were bound (Section 3.1.2.1) was incubated with untagged USP11 or USP11/76-286 
(containing the N-terminal DUSP/UBL1 domains). As a negative control, GST bound to 
     Mw   Son.  Sn.   Prot.  Mw  Son. Sn.  Prot.   Mw   Son.  Sn.   Prot.    
GST-BMI1/1-109   GST-RING2/1-331  GST-RING2/1-159  
 
250 
130 
100 
70 
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35 
 
 
27 
 
 
15 
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glutathione sepharose was used as a bait to verify that USP11 fragments do not interact 
with this 28 kDa protein. Pull downs were carried out as described in Chapter II, Section 
2.6.  Bound proteins were eluted in Laemmli sample buffer and separated by SDS-PAGE. 
No interaction was detectable with Coomassie staining (Figure 3.3). 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.3) USP11 does not interact with GST-fused BMI1/RING and RING2.  
Purified recombinant proteins USP11 and USP11/NTD (USP11/76-286) were incubated with 
resins containing bound GST-RING2/1-331, GST-RING2/1-159, or GST-BMI1/1-109 and then 
washed extensively. The bound proteins were dissociated and separated by SDS-PAGE. Mw 
markers are indicated at the left side of each panel. Red stars indicate migration of USP11 and 
USP11NTD. The Arrows show migration of GST-RING2/1-331, GST-RING2/1-159, and GST-
BMI1/1-109 and GST, from left to right, respectively.  
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In order to confirm that the GST-tag is not interfering with the interaction in the GST 
pull downs, a reciprocal His6-tag pull down experiment was carried out. The His6-
USP11/76-963 (provided by Dr. G. Maertens) and His6-USP11/76-286 were bound to the 
CL-Nickel ChroMatrix beads. Untagged RING2/1-331 was then used in the pull down. As 
a negative control, CL-Nickel ChroMatrix beads alone were used. As shown in Figure 
3.4a, no interaction could be detected in the SDS-page gel between USP11 fragments and 
RING2/1-331. Western blotting using an antibody that specifically recognizes RING2 was 
used to confirm the absence of a specific interaction (Figure 3.4b). 
 
 
 
 
 
 
 
 
Figure 3.4) Interaction of His6-USP11/76-963 and His6-USP11/76-286 with RING2/1-331 analyzed 
by pull-down experiment.  
(a) Purified recombinant protein RING2/1-331 was incubated with resins containing bound His6-
USP11/76-963 and His6-USP11/76-286(NTD) and then washed extensively. The bound proteins 
were dissociated and separated by SDS-PAGE gels and stained with Coomassie. Beads alone ( - ) 
were used as negative control. (b) Western blot detecting RING2/1-331. Mw markers are indicated 
at the left side of each panel. The arrows show migration of RING2/1-331. 
 
RING2/  
1-331 
RING2/  
1-331 
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In previous studies full-length USP11 was used in experiments (Maertens et al, 2010). 
We noticed that removal of the first 75 amino acids of the protein increases the expression 
and, thus, yield of the protein.  To test whether these residues are necessary for the 
interaction, the binding to the same proteins, as reported by Maertens et al. in 2010, was 
tested. Baculovirus produced Flag-tagged mRing1b and mBmi1 (provided by Dr. S. 
Elderkin) and bacterially expressed and purified CBX8-Flag (provided by Dr. G. Maertens) 
were tested for binding to His6-USP11/76-963 and His6-USP11/76-286. CL-Nickel 
ChroMatrix beads were used as a negative control. The beads were washed extensively to 
remove unbound proteins. Western blotting was used to detect interactions, using anti-
Flag-HRP antibody (Figure 3.5). 
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Figure 3.5) His6-USP11/76-963 and His6-USP11/76-286 CL-Nickel ChroMatrix pull downs.  
Purified recombinant Flag-tagged mRing1b, mBmi1 and CBX8 proteins were incubated with 
resins containing bound His6-USP11/76-963 (USP11) and His6-USP11/76-286 (USP11/NTD ) and 
then washed extensively. The bound proteins were dissociated and separated by SDS-PAGE gel 
and stained with Coomassie (a) or, transferred to nitrocellulose membrane and detected with HRP 
conjugated anti-Flag antibody (b). Beads alone ( - ) were used as negative control. Mw markers are 
indicated at the left side of each panel.  
 
 
 
 
The mBmi1 protein was found co-precipitating with our proteins of interest as well as 
with the negative control (Figure 3.5b, lanes 10-12). It is known that Zn2+-binding RING 
domains tend to non-specifically bind to metal chelate affinity resins. Therefore, it is not 
clear whether mBmi1 interacts with the USP11 fragments or not.  The amount of 
baculovirus produced mRing1b protein used in the pull-down was too low, and was not 
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detectable by Western blot (Figure 3.5b, lanes 7-9). In this experiment it appears that 
CBX8-Flag interacts with both USP11 fragments. However, a repeat experiment did not 
confirm pull down of CBX8-Flag with USP11 fragments (Figure 3.6). The signal observed 
in lanes 4-5 in Figure 3.6b is thus most likely due to the sample of lane 3 that ran over into 
these lanes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6) His6-USP11/76-963, His6-SUMO- USP11/306-963 and His6-USP11/76-286 CL-Nickel 
ChroMatrix pull-downs.  
Purified recombinant Flag-tagged CBX8 protein was incubated with resins containing bound His6-
USP11/76-963 (ΔUSP11), His6-SUMO- USP11/306-963 (ΔUSP11-C) and His6-USP11/76-286 
(ΔUSP11-N); washed extensively. The bound proteins were dissociated and separated by SDS-
PAGE gel (a), transferred to nitrocellulose membrane and detected with HRP conjugated anti-Flag 
antibody (b). Beads alone (-) and His6-SUMO protein were used as negative control. Mw markers 
are indicated at the left side of each gel. The arrows show migration of CBX8-Flag. 
 
CBX8-
Flag 
CBX8-
Flag 
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3.2 Discussion  
In 2010, USP11 was described to be present in PRC1 complexes isolated from human cells. 
Interestingly, USP11 regulates the stability of the E3 ligase component of PRC1 (Maertens 
et al, 2010). Due to the high stability of PRC1 complexes in mammalian cells, it may be 
problematic to identify the direct interactions involved between USP11 and the PRC1 
components using immunoprecipitations of deletion fragments. We know that full-length 
GST-tagged USP11 can pull down CBX8, mMel18, mBmi1 and mRing1b produced in a 
cell-free system (Maertens et al, 2010). In this project we aimed to map the interaction 
between USP11 and PRC1 components. 
A direct interaction between different PRC1 core components using yeast two-hybrid 
had previously been established. DB-fusions of MEL18 and BMI1 can bind to AD-fused 
PC, SCE and PH proteins (G. Maertens, unpublished results). Therefore, to determine the 
minimal binding regions involved in a direct interaction between USP11 and PRC1 
components and to circumvent the need to purify different USP11 and PRC1 deletion 
mutants, we initially used a yeast two-hybrid assay. Contrary to our expectations no 
interaction could be detected between AD-USP11 and DB fused MEL18-Flag, 
MEL18/ΔRING-Flag, MEL18/RING-Flag or BMI1-Flag, in AH109 cells, as no colonies 
were formed on the plates selecting for expression of the reporter genes.  
It is possible that the N-terminal fusions with AD and DB domains could interfere with 
the interaction of USP11 with PRC1 components. In addition, poor expression of USP11 
in yeast might be problematic. Given the negative result of the yeast two-hybrid 
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experiments, we used pull-down assays in further attempts to detect an interaction 
between PRC1 components and USP11. Using GST-tagged fusions of PRC1 subunits and 
untagged USP11 fragments, or His6-tagged USP11 fragments and untagged PRC1 
components, we could not confirm a direct interaction in vitro. There are several possible 
explanations for this observation. (i) The 28 kDa GST-tag fused to the N-terminal RING 
domains of BMI1 and RING1B could interfere with the interaction. (ii) BMI1 and 
RING1B are substrates of USP11 and it is known that interactions between enzyme and 
substrate are weak. (iii) PRC1 components are phosphorylated in mammalian cells 
(Elderkin et al, 2007; Liu et al, 2012; Voncken et al, 1999); however our recombinant 
proteins are not phosphorylated. (iv) A strong interaction between USP11 and its 
substrates could be dependent on their ubiquitination status. Proteins used in our study 
were not ubiquitinated. (v) Finally, interaction with USP11 may require a complete PRC1 
complex. 
Maertens et al. detected interactions between GST-USP11 and PRC1 components in 
vitro.  The interactions described were weak as they could only be detected by Western 
blot or by autoradiography. Moreover, using 35S labelled in vitro translated protein, it was 
suggested that the RING domains of RING2 and MEL18 (or the homologous BMI1) 
proteins are involved in the direct interaction with USP11 (Maertens et al, 2010). It is, 
thus, possible that fusion of GST to the N-terminus of BMI1 and RING2 interferes in the 
interaction with USP11.  In the previous report, GST-USP11 was used as bait. GST tag 
forms stable dimmers, which may increase apparent interaction affinity. Our study used a 
USP11 deletion fragment where the first 75 amino acids are omitted. This allowed us to 
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purify high levels of USP11, but it is possible that this region is important for the 
interaction with PRC1. 
In conclusion, we could not confirm strong direct interactions between USP11 
fragments and individual PRC1 components. We suggest that residues between amino 
acid 1-75 might be important for the interaction with PRC1 components, or that more 
than one PRC1 component and/or post translational modification could be necessary for 
high affinity interaction with USP11.  
Alternatively, in future studies, different protein fragments could be expressed and 
purified from insect cells to study the interaction between different USP11 and PRC1 
fragments using in vitro pull downs. The protein production yield in insect cells is usually 
high and the proteins are post-translationally modified, often mimicking protein 
expression in mammalian cells.   
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Chapter IV: Mapping the interaction between RYBP, BMI1 and 
RING2  
It was shown that RYBP, BMI1 and RING2 can form a complex and are sufficient for 
H2A ubiquitination (Gao et al, 2012). BMI1 and RING2 are known to interact via their 
RING domains (Buchwald et al, 2006). In an attempt to characterise the interaction 
between these three PRC1 components, we used in vitro approaches, as described below. 
 
4.1 Results  
Several plasmids were constructed to express different RYBP, BMI1 and RING2 fragments 
in bacteria to investigate the interaction between them (Table 4.1).   
 
 
 
 
 
 
Table 4.1) Plasmid constructs made to express RYBP, BMI1 and RING2/1-331 with different tags. 
 
Plasmids   Antibiotic  
pET-28a-SUMO-BMI1  Kanamycin 
pCFD-H6P-Duet1-BMI1 Spectinomycin 
pET-28a-SUMO-RING2/1-331 Kanamycin 
pGEX-6p-3-RING2/1-331 Ampicillin 
pGEX-6p-1- RYBP  Ampicillin 
pCDF-H6P-RYBP Spectinomycin 
pCDF-H6P-RYBP/BMI1 Spectinomycin 
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4.1.1 Expression and purification of RYBP, BMI1 and RING2  
In order to study the molecular interaction between RYBP, BMI1 and RING2, we 
searched for the highest level of expression and purification of these proteins in different 
conditions.  
 
RYBP 
In the first attempt, a construct containing His6-tagged RYBP was cloned and transformed 
into PC2 cells. The protein expression was induced in a 3 L cell culture at OD600 of 0.9 at 
25 °C for 4 h. After harvesting the cells, the protein was extracted by resuspending the 
cells in a buffer containing 25 mM Tris pH 7.4 and 150 mM NaCl. After sonicating the 
cells a sample was taken to detect the expression level. Another sample was taken after 
clearing the sonicated lysate from debris to detect the extraction level. Samples were 
separated by SDS-PAGE gel and stained with Coomassie (Figure4.1). 
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Figure 4.1) His6-RYBP expression and extraction level.  
Samples from sonicated (Son.) cell lysate and its supernatant (Sn.) were separated by SDS-PAGE. 
Mw marker is indicated at the left side the gel. The arrow indicated the migration of His6-RYBP. 
 
 
 
 
His6-RYBP was purified over a CL-Nickel ChroMatrix and eluted with 200 mM 
imidazole in ten 1-ml fractions. Fractions number 2 - 7 were pooled together and were 
further purified by cation exchange chromatography on a 5-ml HiTrap Sepharose column 
(Figure 4.2).  
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Figure 4.2) His6-RYBP purification steps. 
(a) 10 μl samples from 10 1-ml fractions (lanes 1 to 10) of CL-Nickel ChroMatrix affinity 
purification of His6-RYBP were subjected to SDS-PAGE to detect the protein. (b) Chromatogram 
showing the purification of the protein on the cation exchange. The eluted protein samples were 
subjected to SDS-PAGE to identify the peak of the protein. The arrows indicate the migration of 
His6-RYBP. The X and Y axes show the UV absorption at 280 nm and the number of the eluted 
fraction, respectively. The blue line denotes UV absorption at 280 nm, the brown line reflects the 
conductivity of the sample. The green line indicates the percentage of buffer B used, starting at 5% 
and ending at 100%. 
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A negligible amount of His6-RYBP was eluted from the cation exchange column, 
suggesting that the protein binds irreversibly to the column matrix. In order to enhance 
the expression level, a construct was cloned to express GST-RYBP. It was transformed 
into PC2 cells. Six l of bacterial culture was induced at OD600 of 0.9 for 4 h at 25oC. After 
harvesting the cells, sequential protein extraction was carried out using buffers containing 
25 mM Tris-HCl pH 7.4 and either 150 mM, 250 mM or 500 mM NaCl. Samples were 
taken after sonicating the resuspended cells and after clearing the sonicated lysate from 
debris to estimate the level of protein extracted. The samples were analysed by SDS-PAGE 
and the proteins stained with Coomassie (Figure4.3). 
 
 
 
 
 
 
 
Figure 4.3) GST-RYBP expression and extraction level.  
Commassie stained SDS-PAGE gel of sonicated (Son.) and supernatant (Sn.) of the centrifuged 
cell lysates prepared in different buffers indicate that the extraction condition is best at 500 mM 
NaCl buffer. The arrow indicates the migration of GST-RYBP.  
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   GST-RYBP extracted with a buffer containing 500 mM NaCl (Figure 4.3) was used to 
purify the protein further by binding to Glutathione Sepharose resins. The protein was 
eluted from the resins using 20 mM glutathione in the extraction buffer; in five 0.5 ml 
fractions (Figure 4.4). The GST-tag was cleaved off from the protein using 3C protease. 
The samples from pre- and post-protease treatment were fractionated by  SDS-PAGE and 
the gel stained with Coomassie (Figure 4.4).  
 
 
 
  
 
 
 
Figure 4.4) Purification of GST-RYBP.  
The affinity purification samples were applied to SDS-PAGE gel and Coomassie stained (left 
panel).  The presence of GST-RYBP was confirmed by visualizing the shift in protein size, after 
cleaving the GST tag with 3C protease (right panel). Red stars show the migration of GST-RYBP. 
 
 
All the eluted fractions were pooled together and the protein was purified from the 
glutathione, using dialysis. The protein was concentrated and frozen in liquid nitrogen 
after adding glycerol to 10% final concentration.   
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RING2  
A construct was cloned to express GST-RING2/1-331 based on published results 
(Buchwald et al. 2006). The plasmid was transformed into PC2 cells. Six litres of the cell 
culture was induced to express the protein at OD600 of 0.9 for 4 h at 25oC. The cells were 
harvested and resuspended in 25 mM Tris pH 7.4 and 500 mM NaCl extraction buffer. 
After sonication a sample was taken to estimate the expression level. After clearing the 
sonicated lysate from debris another sample was taken to measure an approximate 
extraction level (Figure 4.5).  
 
 
 
 
 
 
 
Figure 4.5) GST-RING2/1-331 expression and extraction level.  
Commassie blue stained SDS-PAGE gel of sonicated (Son.) and supernatant (Sn.) of the 
centrifuged sonicated cell lysates. The arrow indicates the migration of GST-RING2/1-331.  
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As shown in the Figure 4.5 the expression level of the GST-tagged RING2/1-331 is 
high, however most of the protein remained in the pellet and could not be extracted. 
Nevertheless, we continued with the extracted protein and purified it by binding to 
Glutathione Sepharose resin. GST-RING2 was eluted with 20 mM glutathione in ten 1-ml 
fractions (Figure 4.6a). Fraction number 2 - 6 were pooled together and the GST-tag was 
cleaved off with 3C protease at 4 °C overnight (Figure 4.6b). The protein was further 
purified by size exclusion chromatography and samples from the peak fractions were 
loaded on SDS-PAGE to detect the purified protein (Figure 4.6b). Fraction number 21 to 
25 were pooled together, concentrated and snap frozen in liquid nitrogen after adding 
glycerol to final 10% concentration.  
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Figure 4.6) RING2/1-331 purification steps. 
(a) SDS-PAGE of GST-RING2/1-331 Glutathione Sepharose affinity purification. (b) 
Chromatogram showing the purification on the size exclusion column of RING2/1-331 after 
cleaving the GST-tag by protein protease 3C. The SDS-PAGE of the cleaved and un-cleaved 
protein shows that the protease activity was completed. The eluted protein fractions were 
subjected to SDS-PAGE to identify the peak of the protein. The eluted fractions were applied to a 
SDS-PAGE gel and the peak fractions were pooled together and concentrated. The X and Y axes 
show the UV absorption at 280 nm and the number of the eluted fraction, respectively. The blue 
line denotes UV absorption at 280 nm, the brown line reflects the conductivity of the sample. The 
green line indicates the percentage of buffer B used, 5%  
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BMI1  
Two plasmid constructs were prepared to express untagged-BMI1, His6-SUMO- BMI1. In 
addition, construct encoding GST-BMI1 was provided by Dr. G. Maertens.  
 Firstly, untagged-BMI1 was expressed in 6 L of LB medium for 4 h at 25oC. Cells were 
harvested and the protein was sequentially extracted with three different buffers, differing 
in NaCl concentration; 150 mM, 250 mM or 500 mM NaCl. The sonicated lysates were 
cleared from debris (Figure 4.7).  The extraction level was not sufficient to continue the 
purification. 
 
 
 
 
 
 
Figure 4.7) BMI1 expression and extraction level.  
Commassie stained SDS-PAGE gel of sonicated (Son.) and supernatant (Sn.) of the centrifuged 
sonicated cell lysates in different buffers [containing 150 mM, 250 mM or 500 mM NaCl]. The 
arrow indicates the migration of BMI1.  
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As seen in Figure 4.7 the extraction of the untagged BMI1 is inefficient. To increase the 
solubility of the protein, the construct expressing His6-SUMO-BMI1    was transformed 
into PC2 cells. The protein expression of 6 L cell culture was induced at OD600 of 0.9 for 4 
h at 25oC. The protein was extracted from the harvested cells in four different buffers; 
containing either 50 mM, 150 mM, 250 mM or 500 mM NaCl. The sonicated lysate was 
cleared from debris. The expression and extraction levels were estimated by loading 
samples of sonicated and cleared lysate on the SDS-PAGE gel (Figure 4.8).  
 
 
 
 
 
 
 
Figure 4.8) His6- SUMO-BMI1 expression and extraction level.  
Commassie blue stained SDS-PAGE gel of sonicated (Son.) and supernatant (Sn.) of the centrifuged 
sonicated cell lysates in different buffers [containing either 50 mM, 150 mM, 250 mM or 500 mM 
NaCl. The arrow shows the immigration of His6- SUMO-BMI1. 
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Although the expression level is low, the cleared lysate in the buffer containing 50 mM 
NaCl was chosen for affinity purification on CL-Nickel ChroMatrix. The protein was 
eluted in 200 mM imidazole in ten 1-ml fractions. A sample from each fraction was 
separated by SDS-PAGE and proteins were detected by staining with Coomassie (Figure 
4.9). His6-SUMO-BMI1 was either not eluted from the CL-Nickel ChroMatrix or was 
severely degraded. 
 
 
 
 
 
Figure 4.9) Affinity purification of His6-SUMO-BMI1.  
Samples of eluted protein with 200 mM imidazole in ten 1-ml fractions were loaded on SDS-PAGE 
gel and stained with Coomassie. The arrow shows the immigration of His6- SUMO-BMI1. 
 
 In the next step, we attempted to use a construct for expression of GST-tagged BMI1. 
Six L of transformed Rosetta 2(DE3)pLacI cell culture in TB medium was induced to 
express the protein with 0.1% IPTG at 18 °C for 16-18 h. The protein was extracted using 
the same buffers used in Buchwald et al. (2006). The expression and the extraction level 
can be estimated from the samples taken before and after clearing the lysates from the 
debris, respectively (Figure 4.10). The GST-tagged protein was purified by binding the 
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lysate on Glutathione Sepharose column. The protein was eluted in 20 mM glutathione, 
three times the volume of the resins (Figure 4.10).  The efficiency of the elution was 
estimated by taking a 10 μl sample from the Glutathione Sepharose resins, boiling the 
beads in 50 μl SDS-loading buffer for 2 min and separating it by SDS-PAGE (Figure 4.10). 
 The GST-tag was removed from BMI1 by 3C protease. The protein was further 
purified by cation exchange chromatography on a 5-ml HiTrap SP sepharose column. 
Fraction 13-18 were pooled, concentrated and snap frozen in liquid nitrogen after adding 
glycerol to final 10% concentration (Figure 4.10).   
 
Figure 4.10) Expression, extraction and purification of GST-BMI1.  
(a)The expression (son.), extraction (sn.) and elution levels of GST-BMI1 can be estimated. The 
arrow indicated the migration of GST-BMI1. (b) Further purification was carried out by loading 
the protein on cation exchange column after cleaving the GST-tag by protein protease 3C. The X 
and Y axes show the UV absorption at 280 nm and the number of the eluted fraction, respectively. 
The blue line denotes UV absorption at 280 nm, the brown line reflects the conductivity of the 
sample. The green line indicates the percentage of buffer B used, starting at 10% and ending at 
100% B, 
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Co-expression of PRC1 components in bacteria  
In many cases, where proteins expressed in E. coli are insoluble, co-expression of a 
binding partner might solubilise the protein and allow for co-purification of a functional 
protein-protein complex. GST-RING2 is expressed at very high levels in E. coli but we 
could not efficiently extract the protein. We know that RING2 and BMI1 interact, and 
also that RING2 and RYBP form a complex. With the aim of purifying a hetero-dimeric or 
-trimeric PRC1 subcomplexes, we co-expressed combinations of RING2 with RYBP 
and/or BMI1 in E. coli. 
 
RING2-RYBP 
Compatible plasmid constructs encoding GST-RING2/1-331 and His6-RYBP were co-
transformed and co-expressed in PC2 cells.   After cells were harvested from 6 L culture, 
sequential protein extraction was carried out with buffers containing different 
concentrations of NaCl; 150 mM, 250 mM, 500 mM. Samples were taken before and after 
clearing the sonicated lysate from debris and separated by PAGE to examine the 
expression and extraction levels (Figure 4.11).  
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Figure 4.11) Extraction and expression levels of co-expressed GST-RING2 and His6-RYBP.  
The expression (son.) and extraction (sn.) levels of the co-expression in six different extraction 
conditions were estimated by SDS-PAGE gel. The migration of GST-RING2 and His6-RYBP are 
shown with black and red arrows, respectively. 
 
 
 
Half of the lysate sonicated in 150 mM NaCl was allowed to bind to Glutathione 
Sepharose resin. The protein was eluted with sonication buffer supplemented with 20 mM 
glutathione in ten 0.5-ml fractions.  The other half was cleared over CL-Nickel 
ChroMatrix and eluted with 200 mM imidazole in ten 0.5-ml fractions. Samples from each 
fraction were separated by SDS-PAGE to detect the best purification method (Figure 
4.12).  In GST-affinity purification only the GST-RING2 was eluted.  
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Figure 4.12) Affinity purification of co-expressed GST-RING2/1-331 and His6-RYBP extracted in 
150 mM NaCl buffer. 
(a)  Samples eluted from CL-Nickel ChroMatrix in 10 1-ml fractions were separated by SDS-
PAGE. Fractions two to nine, containing only GST-RING2/1-331, were pooled together for 
further purifications. (b) Samples eluted from glutathione Sepharose resins in 10 1-ml fractions 
were separated by SDS-PAGE. Fractions 3 - 9, containing both proteins were pooled together for 
further experiments.  
 
 
 
GST-RING2/1-331 in fractions 2 - 9 were pooled together for further experiments, 
concentrated and snap-frozen in liquid nitrogen. His6-affinity purification allowed us to 
elute GST-RING2 and His6-RYBP as complex, albeit at very low yield (Figure 4.12a). 
Fraction numbers 3 - 9 were pooled together. After removing the tags by 3C protease, the 
proteins were purified by size exclusion chromatography (Figure 4.13). None of the 
proteins could be detected in the fractions eluted from the column; examined on 
Coomassie-stained SDS-PAGE gel. 
GST- 
RING2 
/1-331 
GST- 
RING2 
/1-331 
His6-
RYBP 
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Figure 4.13) Purification of RING2 and RYBP by size exclusion chromatography.   
Samples from the peak fractions eluted from size exclusion column were tested on SDS-PAGE gel. 
Proteins could not be detected. The X and Y axes show the UB absorption at 280 nm and the 
number of the eluted fraction, respectively. The blue line denotes UV absorption at 280 nm, the 
brown line reflects the conductivity of the sample. The green line indicates the percentage of 
buffer B used, 5%.  
 
 
 
In an attempt to increase the solubility of RING2, constructs were made to express 
His6-SUMO-RING2, which was co-transformed into PC2 cells with a plasmid expressing 
His6-RYBP. Protein expression was induced in 6 L culture at OD600 of 0.9 for 4 h at 25oC. 
Cells were harvested and the proteins were extracted in four different buffers. The 
expression and the extraction levels were estimated by taking samples from before and 
after clearing the lysate from debris (Figure 4.14). The expression level of His6-SUMO- 
RING2 had drastically decreased in comparison with GST-RING2, co-expressed with 
His6-RYBP. The extraction level, compared to GST-RING2/ His6-RYBP co-expression, 
had not improved; therefore, the experiment was terminated.  
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Figure 4.14) Expression level and extraction efficiency of co-expressed His6-SUMO- RING2 and 
His6-RYBP.  
Extraction was done in different conditions. His6-SUMO-RING2 and His6-RYBP migration is 
indicated with black and red arrows, respectively.  
 
 
RING2-BMI1 
GST-tagged RING2 and untagged BMI1 were co-transformed into PC2 cells.  The protein 
expression was induced at OD600 of 0.9, in 6 L culture, for 4 h at 25oC. The cells were 
harvested and proteins were extracted in two sequential conditions, using buffers 
containing either 0 mM or 100 mM NaCl. Samples were taken before and after clearing 
the lysate from debris, to estimate the extraction and expression levels (Figure 4.15). The 
extraction level for both proteins was very low; therefore, the experiment was 
terminated.   
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Figure 4.15) Expression level and extraction efficiency of co-expressed GST-RING2 (black arrow) 
and BMI1 (red arrow).  
 
 
 
 
We also tried the co-expression of His6-SUMO-RING2 (described above) with untagged 
BMI1 in the PC2 strain. The protein expression was induced for 4 h at 25oC. The cells 
were harvested and proteins extracted in four conditions differing in NaCl concentration. 
The expression and extraction levels were estimated by taking samples before and after 
clearing the sonicated lysate from debris (Figure 4.16a).  The extraction level was shown 
to be sufficient in 0 mM NaCl extraction buffer and was chosen for further purification by 
clearing the lysate over CL-Nickel ChroMatrix. The proteins were eluted in ten 1-ml 
fractions with 200 mM imidazole, visualized on SDS-PAGE gel stained with Coomassie 
(Figure 4.16b). The protein complex could not be eluted from the affinity purification 
column. The experiment was terminated.  
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Figure 4.16) Co-expressed His6-SUMO-RING2 and BMI1. 
(a) Expression and Extraction of co-expressed His6-SUMO-RING2 and BMI1 in different 
conditions. (b) Samples eluted from CL-Nickel ChroMatrix in 10 1-ml fractions were separated 
by SDS-PAGE.  
 
  
RING2-BMI1-RYBP 
It is clear that although RING2, RYBP and BMI1 can be expressed at relatively high levels, 
extraction of a dimer was very inefficient suggesting that either the interaction between 
the two proteins is very weak and they don't form a complex in E. coli or that the hetero-
dimeric complexes are insoluble. We hypothesized that maybe a trimeric complex would 
be more soluble and thus tried co-expression of all three of these subunits in E. coli. 
Expression of proteins was induced in 6 L culture at OD600 of 0.9 for 4 h at 25oC. In first 
instance we co-transformed the PC2 strain with plasmids encoding for GST-RING2, His6-
RYBP and His6-SUMO-BMI1. These three plasmids each contain a different resistance 
cassette and co-transformed bacteria can thus be selected by growing the cells in the 
presence of ampicillin, spectinomycin and kanamycin. After cells were harvested, proteins 
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were extracted in four conditions differing in NaCl concentration; 0, 100, 250 and 500 
mM. The expression and extraction levels were estimated by taking samples from before 
and after clearing the sonicated lysate from debris, loaded on SDS-PAGE gel and stained 
with Coomassie (Figure 4.17). GST-RING2 was not significantly eluted in either of the 
buffers used. His6-RYBP was eluted most efficiently in extraction buffer containing 500 
mM NaCl and BMI1 in 0 mM NaCl. As proteins in form of a complex could not be eluted, 
the experiment was terminated.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17) Expression and extraction level of GST-RING2, His6-RYBP and His6-SUMO-BMI1 co-
expression.  
Proteins were extracted in four different conditions, to find the best extraction condition. Each 
protein is best extracted in different condition.      
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We also tried the combination of His6-SUMO-RING2 with His6-RYBP and untagged 
BMI1. After inducing the protein expression for 4 h, the cells were harvested and 
underwent the sequential protein extraction procedure. The proteins were extracted 
under four conditions, differing in NaCl concentration of the extraction buffer; 0 mM, 100 
mM, 250 mM and 500 mM. Samples were taken from before and after the sonicated lysate 
were cleared from debris, to estimate the expression and extractions levels (Figure 4.18a).  
 Unlike BMI1 which had shown increased expression levels, compared to previous co-
expression, the expression levels of RING2 and RYBP had considerably decreased. None 
of the three proteins could be efficiently extracted, the experiment was therefore 
terminated. 
 
 
 
 
 
 
Figure 4.18) Co-expression of His6-SUMO-RING2, His6-RYBP.  
Expression and extraction of co-expressed His6-SUMO- RING2, His6-RYBP and untagged BMI1 in 
four conditions.  
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4.1.2 Investigating BMI1-RYBP interaction using pull down assays  
The interaction between BMI1 and RYBP was investigated using the GST-pull down 
assay. It was shown that the RING domain of Bmi1 interacts with the RING domain of 
Ring1b (Li et al, 2006; Buchwald et al, 2006). Therefore in this experiment, GST-RING2 
was used at positive control and GST as negative control. GST-RYBP, GST-RING2 and 
GST were mixed separately with BMI1 in binding buffer and complexes were allowed to 
form by gentle rocking at 4oC. Two hours later, equilibrated glutathione sepharose resin 
was added to capture the GST-tagged protein and the complexes they may have formed. 
After 3 h gentle rocking at 4oC, the beads were extensively washed. Bound proteins were 
eluted by boiling the beads in Laemmli sample buffer and were then separated on SDS-
PAGE gels. The gels were stained with Coomassie (Figure 4.19a). As can be seen in lane 2 
of Figure 4.19 a, very little BMI1 was used for the pull-down. We thus also ran the 
samples on gel for Western blot detection with an anti-BMI1 antibody (Figure 4.19b). As 
expected, BMI1 is recovered with GST-RING2, thus confirming the interaction between 
these two proteins. The BMI1 was not pulled-down with GST-RYBP since the amount of 
BMI1 detected by Western blot is similar to background interaction with GST (compare 
lanes 1 and 2 with lane 3 in panel b) suggesting that BMI1 and RYBP do not interact 
directly, or minimally do not display a high affinity interaction.   
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Figure 4.19) GST-RYBP glutathione sepharose pull downs.  
Purified BMI1 and GST-RYBP or GST-RING2 (positive control) were mixed with glutathione 
sepharose resins for 3 h and the beads were washed extensively. Bound proteins were dissociated 
and separated by SDS-PAGE gel and stained with Coomassie (a), or transferred to a nitrocellulose 
membrane and detected with anti-BMI1 antibody (b) to detect BMI1 in the pull downs. GST was 
used as negative control. Black and red arrows indicate migration of BMI1 and GST, respectively.   
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4.2 Discussion  
It was shown that RING2, MEL18 (BMI1 homolog) and RYBP can mono-ubiquitinate 
H2A on nucleosome substrates in vitro (Tavares et al, 2012).  In this project we aimed to 
purify three different PRC1 components (BMI1, RING2 and RYBP) and investigate their 
interactions. We also aimed to form a multi-component PRC1 complex using these three 
proteins and investigate whether this increases the affinity for USP11.    
The main challenge in this project was to optimize the expression and extraction levels 
in bacteria. For each of these proteins, different tags, bacteria culture mediums, and 
temperatures were tested to identify the best condition in which bacteria best express the 
desired protein. In addition, we also used different extraction conditions, but were 
unsuccessful in purifying the recombinant proteins.  
We also tested the possibility of co-expressing different combinations of proteins in 
bacteria. Co-expression of proteins in the bacteria cell could improve the stability and 
solubility of the proteins. In some cases the co-transformation increased the expression of 
one or both proteins compared to when they were expressed separately. However, it was 
observed that each protein could be extracted from the bacteria in different extraction 
condition, and none of the proteins formed a stable complex and, thus, could not be 
purified as a complex.  
Even though we could not purify high levels of the PRC1 components, we had enough 
protein to investigate whether there is a direct interaction between BMI1 and RYBP. 
Whilst the interaction between RING2 and BMI1 could be confirmed, under the same 
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conditions we could not observe a direct interaction between BMI1 and RYBP. It is 
possible that there is no direct interaction between RYBP and BMI1, and the trimeric 
complex exists by direct interaction of these two proteins with RING2. Alternatively, it is 
possible that the GST-tag on RYBP sterically interferes with the interaction, a reciprocal 
pull down, using His6-tagged BMI1 and untagged RYBP is thus required to confirm our 
observation.  
We can conclude that production of pure recombinant RING2, BMI1 and RYBP at 
high levels is difficult to achieve in E. coli. Currently, studies are being carried out in our 
group, by Dr. Maertens, to express the proteins in Sf9 insect cells to potentially improve 
the protein expression level.   
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Chapter V: Structural characterisation of USP11 N-terminal 
domain 
The X-ray crystal structure of USP15 and USP4 DU has been solved (Harper et al, 2011; 
Bacik et al, 2009).  In an attempt to characterise the structure of USP11/DU we used a 
range of USP11 deletion constructs to obtain crystals and determine its structure.  
 
5.1 Results  
Several plasmids were made in the effort to solve the structure of USP11 DU (Table 5.1).  
 
 
 
 
 
 
 
 
 
 
Table 5.1) Plasmid constructs made to express different fragments of USP11 DU.  
These plasmids contain a streptinomycin resistant gene. 
 
 
Plasmids   
pCDF-H6P-Duet1-USP11/1-286 
pCDF-H6P-Duet1-USP11/76-286 
pCDF-H6P-Duet1-USP11/76-
286[E106A/K107A] 
pCDF-H6P-Duet1-USP11/76-
286[K146A/E147A] 
pCDF-H6P-Duet1-USP11/76-
286[K278A/K279A] 
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5.1.1 Expression and purification of USP11 N-terminal fragments.  
A construct containing full-length GST-USP11, available in the laboratory and provided 
by Dr. G. Maertens, was used to express the protein in 6 L TB medium in Rosetta 
2(D3)pLacI E. coli cells at 16 °C for 20 h. Protein was extracted and eluted in ten 1ml-
fractions with 20 mM glutathione (Figure 5.1).  
 
 
 
 
 
 
 
Figure 5.1) Affinity purification of GST-USP11.  
Samples of eluted protein were separated by SDS-PAGE. The arrow indicates the migration 
position of full-length GST-USP11.  
  
 
 
Since the large scale expression of full length USP11 resulted in a negligible protein 
yield, we decided to focus our efforts on expression and purification of fragments of 
USP11.  
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In order to determine the X-ray structure of the N-terminal region of USP11, plasmid 
constructs were cloned encoding this region of USP11 and containing both DUSP (76-195) 
and UBL1 (196-286) domains. The function and structural significance of the first 76 
amino acid is not known. Two constructs encoding His6-tagged USP11/1-286 and 
USP11/76-286 gene were kindly provided by Dr. G. Maertens. Each of these constructs 
was transformed into E. coli PC2 strains. Six L LB medium supplemented with the 100 
g/ml spectinomycin (Melford) were used to grow the bacterial culture to OD600 of 0.8. 
The bacteria were induced by adding 0.1% IPTG to the culture and incubating it at 25 °C 
for 4 h. The cells were harvested and after clearing the sonicated lysate from debris, the 
His6-tagged proteins were purified over a CL-Nickel ChroMatrix (Figure 5.2a and 5.3a). 
The His6-tag was removed by human rhinovirus 14 3C protease overnight at 4 °C (Figure 
5.2b and 5.3b). The cleaved protein was further purified by anion exchange 
chromatography (Figure 5.2b and 5.3b), followed by size exclusion chromatography 
(Figure 5.2c and 5.3c).  
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Figure 5.2) His6-USP11/1-286 purification steps.  
(a) SDS-PAGE of His6-USP11/1-286 CL-Nickel ChroMatrix affinity purification. Arrowhead 
indicates migration position of His6-USP11/1-286. (b) Chromatogram showing the purification on 
the anion exchange HiTrap Q column (upper panel) of USP11/1-286 after cleaving the His6-tag by 
human rhinovirus 14 3C protease. The protein was eluted with a linear salt gradient, from 15% B 
to 100% B. The SDS-PAGE of the cleaved and un-cleaved protein shows that the tag was fully 
removed. The eluted protein fractions were subjected to SDS-PAGE to identify the peak of the 
protein. Arrowhead indicates migration position of USP11/1-286. (c) Purification of the fragment 
was completed by size exclusion chromatography. The protein was eluted in 20% B.  The eluted 
fractions were separated by SDS-PAGE. Fraction numbers are indicated at the top of the gel, size 
of the Molecular weight marker is indicated at the left side of the gel. Arrowhead indicates 
migration position of USP11/1-286. The X and Y axes show the UB absorption at 280 nm and the 
number of the eluted fraction, respectively.  Blue lines denote UV absorption at 280 nm, brown 
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lines reflect the conductivity of the sample and the green lines indicate the percentage of high salt 
containing buffer B used. 
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Figure 5.3) His6-USP11/76-286 Protein purification steps.  
(a) SDS-PAGE of His6-USP11/76-286 CL-Nickel ChroMatrix affinity purification. Arrowhead 
indicates migration position of His6-USP11/76-286. (b) Chromatogram showing the purification on 
the anion exchange HisTrap Q column (upper panel) of USP11/76-286 after cleaving the His6-tag 
by human rhinovirus 14 3C. The protein was eluted with a linear salt gradient, from 15% B to 
100% B. The SDS-PAGE of the cleaved and un-cleaved protein shows that the protease activity 
was completed. The eluted protein fractions were subjected to SDS-PAGE to identify the peak of 
the protein. Arrowhead indicates migration position of USP11/76-286.  (c) Purification of the 
fragment was completed by size exclusion chromatography. The protein was eluted in 20% B.  The 
eluted fractions were applied to a SDS-PAGE gel and the peak fractions were pooled together and 
concentrated to 20mg/ml. Arrowhead indicates migration position of USP11/76-286. The X and Y 
axes show the UB absorption at 280 nm and the number of the eluted fraction, respectively. The 
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blue line denotes UV absorption at 280 nm, the brown line reflects the conductivity of the sample. 
The green line indicates the percentage of buffer B used. 
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5.1.2 Crystallization of USP11/76-286  
USP11/1-286 was expressed at lower levels and could not be purified from low-molecular 
weight contaminants (Figure 5.2). In contrast, USP11/76-286 was expressed at very high 
levels and the purification was successful (Figure 5.3). Therefore, we focused on 
crystallisation screening with USP11/76-286 construct.   
In the first attempt USP11/76-286 was concentrated to 9 mg/ml and subjected to 
crystallization screening using 11 different commercially available sparse matrix screens 
(96 different conditions per plate) in sitting drop format. Crystals were formed in 6 
different conditions forming clusters of needles/rods (Figure 5.4). However, most drops on 
the screens remained clear even after prolonged incubation of crystallization plates, 
indicating that the construct is highly soluble.  
 
 
 
 
 
 
 
Figure 5.4) USP11/76-286 (9mg/ml) crystals. 
Crystals grew into star shaped bundle of needle rods after 7 days at 18oC. 
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Therefore, in the next step we repeated the crystallization screening using purified 
USP11/76-286 that was concentrated to 20 mg/ml. We observed crystals shaped in 
hexagonal rods in a number of crystallization conditions. From the original screening 
many conditions allowed the protein fragments to form hexagonal rod crystals. These 
conditions were chosen and used to optimize the crystal-growth conditions; we varied 
pH, precipitant and buffer concentration, and used an additive screen (Hampton 
research), to optimize crystallization conditions (Figure 5.5).  
The best crystals grew at 18 °C in hanging drops the presence of 13 % (w/v) 
polyethylene glycol (PEG)-8,000, 0.2 M MgCl2 and 0.1 M Tris-HCl pH 6.5, within 72 h. 
For cryoprotection, the crystals were soaked in solution in which crystals were formed, 
supplemented with PEG-8,000 and glycerol (to a final concentration of 20 % and 15 %, 
respectively) and snap-frozen by immersion in liquid nitrogen. In total 134 crystals were 
taken to the beam line. They typically diffracted with a resolution ranging from 4.8 to 8 Ǻ 
and the best crystal diffracted at 3.6 Ǻ resolution. Data statistics of the crystal used for 
data collection, calculated by Dr. Maertens and Prof. Cherepanov, are summarized in 
Table 5.2. The space group was assigned to P6222 with unit cell parameters of a = b = 81.5 
Ǻ, C = 320.9 Ǻ (Figure 5.6). 
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Figure 5.5) USP11/76-286  crystals in the form of a hexagonal rods grown in different conditions 
using 20 mg/ml protein (eg. 12% PEG8K, 0.2M MgCl2, 0.1M Tris pH 7.7; or 20% PEG3350, 0.2M 
Na2SO4, 0.1M BTP pH 7.5. 
Figure 5.6) An image of diffraction pattern of a USP11/76-286 crystal.  
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Table 5.2) X-ray data-collection and refinement statistics. Values in brackets are for the highest 
resolution shell. 
 
 
5.1.3 Expression and purification of three mutant forms of USP11/76-286 
Amino acids with long flexible side chains might interfere with the packing of the protein 
into the crystal. Substitution of flexible surface exposed amino acids for Ala residues is 
known as surface entropy reduction approach. In an attempt to obtain crystal forms of 
USP11/76-286 diffracting to a higher resolution we used Surface Entropy Reduction 
prediction (SERp) server version 1.20  (Goldschmidt et al, 2007) to find suitable residues 
in this construct for mutagenesis. Obtaining the protein structure with higher resolution 
will help up us to solve the structure with improved details. Subsequently we can compare 
Refinement  
No. reflections:  
   work 7361 
   free 630 
Rwork/Rfree (%) 36.25/40.97 
No. atoms:   
   protein 2524 
Average B (Å2):  
   protein 74.39 
R.m.s. deviations:  
   bond lengths (Å) 0.005 
   bond angles (o) 1.151 
Ramachandran plot 
(%): 
 
   favored 95.89 
   outliers 1 
Data collection  
Space group P6222 
Cell dimensions  
    a, b, c (Å) 
82.49, 82.49, 
321.36 
Resolution (Å) 3.60 
Rmerge (%) 14.1  (176.4) 
<I /(I)> 6.2  (1.1) 
Completeness (%) 98.4 (99.9) 
Redundancy 4.5 
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the USP11 DU structure with other solved DU structures with enhanced analytical 
outcome.  
At three sites in USP11/76-286, two flexible amino acids are present in close proximity; 
Lys and Glu.  Mutations were introduced in the fragment at each of these sites, separately, 
to replace Lys and Glu with a small amino acid, Ala. Constructs were cloned encoding for 
either His6-USP11/76-286[E106A/K107A], His6-USP11/76-286[K146A/E147A] or His6-
USP11/76-286[K278A/K279A] and transformed into E. coli PC2 cells. Six L LB cultures 
were induced at 25 °C for 4 h. Cells were harvested and the sonicated lysate was cleared 
from debris by centrifugation. The His6-tagged proteins were purified over a CL-Nickel 
ChroMatrix (Figure 5.7a, 5.8a, 5.9a). The His6-tag was removed by human rhinovirus 3C 
protease cleavage overnight at 4oC. The cleaved proteins were further purified by anion 
exchange chromatography (Figure 5.7b, 5.8b, 5.9b), followed by size exclusion 
chromatography (Figure 5.7c, 5.8c, 5.9c). 
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Figure 5.7) His6-USP11/76-286[E106A/K107A] Protein purification steps.  
(a) SDS-PAGE of His6-USP11/76-286 CL-Nickel ChroMatrix affinity purification. Arrowhead 
indicates migration position of the tagged protein. (b) Chromatogram showing the purification on 
the anion exchange column (upper panel) of USP11/76-286 after cleaving the His6-tag by protein 
protease human rhinovirus 3C. The protein was eluted with a linear salt gradient, from 15% B to 
100% B. The SDS-PAGE of the cleaved and un-cleaved protein shows that the protease activity 
was completed. The eluted protein fractions were subjected to SDS-PAGE to identify the peak of 
the protein. (c) Purification of the fragment was completed by size exclusion chromatography. 
The protein was eluted with 20% B. The eluted fractions were separated on 11% SDS-PAGE gel 
and the peak fractions were pooled together and concentrated to 6 mg/ml. Arrowhead indicates 
migration position of the untagged protein in (b) and (c). The X and Y axes show the UB 
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absorption at 280 nm and the number of the eluted fraction, respectively. The blue line denotes 
UV absorption at 280 nm, the brown line reflects the conductivity of the sample. The green line 
indicates the percentage of buffer B used. 
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Figure 5.8) His6-USP11/76-286[K146A/E147A] Protein purification steps.  
(a) SDS-PAGE of His6-USP11/76-286 CL-Nickel ChroMatrix affinity purification. Arrowhead 
indicates migration position of the tagged protein. (b) Chromatogram showing the purification on 
the anion exchange column (upper panel) of USP11/76-286 after cleaving the His6-tag by protein 
protease human rhinovirus 3C. The protein was eluted with a linear salt gradient, from 15% B to 
100% B. The SDS-PAGE of the cleaved and un-cleaved protein shows that the protease activity 
was completed. The eluted protein fractions were subjected to SDS-PAGE to identify the peak of 
the protein. (c) Purification of the fragment was completed by size exclusion chromatography. 
The protein was eluted with 20% B. The eluted fractions were separated on 11% SDS-PAGE gel 
and the peak fractions were pooled together and concentrated to 5 mg/ml. Arrowhead indicates 
migration position of the untagged protein in (b) and (c). The X and Y axes show the UB 
absorption at 280 nm and the number of the eluted fraction, respectively. The blue line denotes 
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UV absorption at 280 nm, the brown line reflects the conductivity of the sample. The green line 
indicates the percentage of buffer B used. 
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Figure 5.9) His6-USP11/76-286[K278AK279A] Protein purification steps.  
(a) SDS-PAGE of His6-USP11/76-286 CL-Nickel ChroMatrix affinity purification. (b) 
Chromatogram showing the purification on the anion exchange column (upper panel) of 
USP11/76-286 after cleaving the His6-tag by protein protease human rhinovirus 3C. The protein 
was eluted with a linear salt gradient, from 15% B to 100% B.  The SDS-PAGE of the cleaved and 
un-cleaved protein shows that the protease activity was completed. The eluted protein fractions 
were subjected to SDS-PAGE to identify the peak of the protein. (c) Purification of the fragment 
was completed by size exclusion chromatography. The protein was eluted with 20% B. The eluted 
fractions were applied to a SDS-PAGE gel and the peak fractions were pooled together and 
concentrated to 8.5 mg/ml. Arrowhead indicates migration position of the protein. The X and Y 
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axes show the UB absorption at 280 nm and the number of the eluted fraction, respectively. The 
blue line denotes UV absorption at 280 nm, the brown line reflects the conductivity of the sample. 
The green line indicates the percentage of buffer B used. 
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5.1.4 Crystallization of USP11/76-286[K278A/K279A] 
Among the three USP11/76-286 mutants, USP11/76-286[K278A/K279A] was expressed 
and purified most successfully. USP11/76-286[K278A/K279A] could be concentrated up to 
8.5 mg/ml which was used in crystal screening; mutants USP11/76-286[E106A/K107A] 
and USP11/76-286[K146A/E147A] were less soluble. USP11/76-286[K278A/K279A] was 
used to screen for an intact crystal form in 11 standard commercially available screening 
conditions (1:1 ratio), and the crystallization plates were incubated at 18oC. Crystallization 
was not observed in any of the conditions.   
 
5.1.5 Analysis of the USP11/76-286 structure  
The structure of USP11/76-286 was solved by molecular replacement using Phaser 
(McCoy et al, 2007) and refined in Phenix (Adams et al, 2010) , by Prof. Cherepanov and 
Dr. Maertens. The electron density map was visualized using Coot software (Emsley et al, 
2010) and the structure was analysed with PyMol (http://www.pymol.org) (Figure 5.10a), 
with Dr. Maertens supervision. The USP11/76-286 structure contains two molecules per 
crystal unit. We used the Protein Interfaces, Surfaces and Assemblies service (PISA) 
(Krissinel and Henrick, 2007) to calculate the likelihood of the observed dimers in the 
crystals to be biologically significant. PISA uses physical-chemical models of protein-
protein interactions to identify chemically stable complexes in crystal packing. Based on 
PISA, interface scored 0.000 in Complex Formation Significance Score (CSS) for 
USP11/76-286. Therefore, USP11/76-286 fragment, unlike the USP4/DU, is not predicted 
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to form functional dimers. This is consistent with elution of the protein construct from 
gel filtration columns.  
Crystals belonged to the space-group P6222. The structure was solved by molecular 
replacement using the coordinates from Protein Data Bank entry 3JYU (Bacik et al, 2009) 
(Figure 5.10). Indeed, both the DUSP and UBL domains could be identified in our 
USP11/76-286 crystals using the coordinates of the homologous mouse USP4/NTD 
structure. The DU finger which links the DUSP and UBL domains in USP15 and USP4 
(Harper et al. 2011; Bacik et al, 2009) could not be assigned in our structures due to the 
relatively low resolution of our diffraction data. The electron density map of USP11/UBL1 
is shown in Figure 5.11, drawn at 1 σ.   
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Figure 5.10) USP11 N-terminal domain structure.  
(a) Schematic representation of USP11 highlighting the overall predicted domain organization 
(using the protein homology search tool SMART) and the location of catalytic residues (UCH1 and 
UCH2). DUSP and UBL1 domains are shown in red and blue respectively. (b) USP11/76-286 DUSP 
(red) and Ubl1 (blue) domains in cartoon representation. The DU finger β-hairpin structure is not 
defined because of low resolution. (c) Two parallel dimeric arrangements of the protein present in 
the crystal packing unit. Chain A is shown in bright red (DUSP) and blue (UBL1) and chain B is 
shown in faded red (DUSP) and blue (UBL1).  
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Figure 5.11) Close-up of region in USP11/UBL1 with electron density map drawn at 1 .  
  
 
 
 
 
 
 
 
 
116 
 
 
The cartoon structure of USP11/DU was aligned to the homologous region of the USP4 
structure (Figure 5.12). The alignment showed that overall structure of the DUSP-UBL 
region of USP11 is organized in a similar way to that of USP11. However, there are slight 
adjustments in relative orientations of the DUSP and UBL domains.  
 
Figure 5.12) Cartoon structure of USP11 N-terminal aligned with USP4 N-terminal domains. 
The USP11/NTD is shown in blue and the USP4/NTD is shown in red. DUSP domain of USP4 is 
shifted away from the USP11; however the Ubl1 domains are more closely aligned.   
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5.2 Discussion 
The crystal structure of USP4/DU and USP15/DU with a resolution of 2.37 Å and 1.50 Å, 
respectively, has been published (Bacik et al, 2009; Harper et al, 2011). It was predicted 
that USP11/DU would have a different configuration from USP15 and USP4, especially at 
its DU finger (Harper et al, 2011). In this project we aimed to solve the crystal structure of 
a homologous USP11/DU fragment. Expression and purification of USP11/1-286 was 
difficult since the protein was expressed at low levels, and large amounts of pure protein 
needed for crystallography were impossible to obtain. The first 76 amino acids, which 
have no predicted functional or structural significance, were removed from the fragment. 
It was shown that USP11/76-286 can be produced and purified at high levels and that this 
protein fragment was highly soluble.  
The proteins crystallized as hexagonal rods. The structure of USP11/76-286 was 
determined by X-ray diffraction analysis and refined to a 3.6 Ǻ resolution. USP11/76-286 
and mouse USP4/8-227 share 48% sequence conservation, of which 35.7% of the residues 
are identical. The coordinates from the PDB entry of mouse USP4/NTD (3JYU) (Bacik et 
al, 2009), was thus used to solve the structure by molecular replacement.  
In each crystal unit, two proteins were present; chain A and B. Interestingly, more 
residues are missing from chain B in electron density maps than chain A, suggesting a 
more flexible packing of this protein chain within the crystal. The average B factors for 
chain A and B are 57.5 and 94.8, respectively (Baverage, CCP4 program suite 6.3.0). The 
region connecting USP11 DUSP and UBL domains could not be built due to low 
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resolution of X-ray diffraction data. However, phased electron density suggested that it 
likely adopts a structure similar to that of the DU finger observed in USP4 (Figure 5.12). 
Our data provide an outline to understand the structure and function of the DU 
subfamily. 
With the aim of increasing the resolution of our X ray data, mutations were introduced 
that were predicted to have an impact on crystal packing. However, these mutant 
proteins were not able to crystallize under the conditions tested. After determining the 
crystal structure of WT USP11/76-286 we were able to investigate the reasons behind 
lack of crystal formation. It was revealed that K287 mutation into A could potentially 
result in destabilizing a loop located at the interface of two protein chain in the crystal 
unit (Figure 5.13).  
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Figure 5.13) Position of K278/K279 mutations in the USP11/76-286 crystal structure.  
The cartoon structure of the protein, on the left, is oriented in the same way as Figure 5.10c. The 
stick structure of the point mutations is coloured green on both chains. The stick structure of 
residues D280 and T282 are also shown. The side chain of K278 is likely to interact with the side 
chains of D280 (distance 3.2 Ǻ) and T282 (distance 2.4 Ǻ) via hydrogen bonds. K278 mutation 
into A would take away these side chains, thus, destabilizes the loop which could obstruct the 
crystal packing.  
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Before we obtained a crystal that diffracted at 3.6 Å resolution, we used the PHYRE 
prediction software (PHYRE Protein Fold Recognition Server version 2.0) to determine 
whether some flexible residues could be removed from our construct. We designed a 
truncated fragment of USP11 NTD; USP11/76-278 278 in which the C-terminal eight 
residues were removed (data not shown). Unfortunately, this protein fragment did not 
crystallize. In our crystal structure of USP11/76-286, the C-terminus of the fragment 
makes important crystal contacts, explaining why further truncations could not form the 
same crystals. 
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Conclusions and future work 
By sequential chromatin immunoprecipitation, Maertens and colleagues showed that 
various distinct PRC1 complexes bind simultaneously and interdependently to the same 
region of the INK4a/ARF locus which cause de-repression of p16INK4a and, hence, 
senescence-associated proliferative arrest (Maertens et al, 2009). Further studies showed 
that USP11 co-purifies with MEL18 and BMI1 complexes from mammalian cells, binds to 
several PRC1 components and regulates the stability of the E3 ligase subunit of PRC1, 
preventing their proteasomal degradation. Hence, shRNA-mediated knockdown of USP7 
and USP11 causes de-repression of p16INK4a and dislodgement of PRC1 components from 
the locus, through the increased turnover of chromatin-bound MEL18 and BMI1 
(Maertens et al, 2010). GST-USP11 can pull down CBX8, mouse Mel18, mBmi1, and 
mRing1b produced in a cell-free system (Maertens et al, 2010).  
Oncogene induced senescence is observed in premalignant lesions. Tumour progression 
requires bypass or escape from senescence (Ruas and Peters, 1998). The PcG proteins are 
often over-expressed in tumours and are thought to contribute to unlimited cell 
proliferation typical of cancer cells (Schuring et al, 2010; Klauke et al, 2011). Reinstating 
senescence in tumour cells is a desirable outcome in cancer therapy. Further 
characterisation of the interaction between USP11 and the PRC1 components and, thus, 
possibly influencing the stability of PcG proteins in the cell with the aim of reinstating 
senescence, is a first step of a long-term goal to develop an anti-cancer drug. 
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In this project we aimed to map the interaction between USP11 and PRC1 components. 
We used two systems to investigate the interaction; yeast two-hybrid and in vitro pull 
down. We did not detect strong interactions between USP11 fragments and individual 
PRC1 components. In future studies we suggest to use USP11/1-286 in the in vitro pull 
down studies; because residues 1-75 may play an important stabilizing part in the 
interaction. One of the reasons that we were not able to detect a high affinity USP11-
PRC1 interaction in vitro might be the lack of post-translational modification. Another 
likely reason for the apparent lack of interaction between USP11 and PRC1 proteins is 
that a complete PRC1 complex may be required for the interaction. In future studies, 
proteins could be expressed in insect cells, where post-translational modifications take 
place and expression levels could be higher.  
In 2006 it was reported that Ring1b and Bmi1 interact directly via their RING domains 
and the crystal structure of regions involved in the interaction was solved (Buchwald et al, 
2006). Gao et al. identified six distinct PRC1 complexes with different genomic 
localizations, suggesting that distinct PRC1 subunit dependent recruitment pathways may 
be at work. It was also shown that RYBP, BMI1 and RING2 can ubiquitinate H2A (Gao et 
al, 2012), independent of H3K27me3 activity of PRC2 (Tavares et al, 2012). In this study, 
we aimed to map the interaction between RING2, BMI1 and RYBP. We tried to purify (or 
co-purify) these proteins from bacteria culture in high quantity to use in in vitro pull 
down; however, we faced a challenge in identifying the best expression, extraction and 
purification methods and failed to obtain these protein in high levels. After mapping the 
interaction regions the ultimate goal was to determine structure of the protein-protein 
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complexes. This remains a goal of the laboratory and experiments are being carried out to 
co-express multisubunit PRC1 subcomplexes in insect cells in an attempt to improve the 
expression levels.  
To date, the crystal structure of the DUSP-UBL domains of two proteins closely related 
to USP11, namely USP4 and USP15, have been solved. In this project we identified a 
fragment of the amino terminal domain of USP11 that encompasses the DUSP-UBL 
domains and that can be produced and purified in large quantities: USP11/76-286. We 
were able to crystallize this fragment under several conditions, performed several rounds 
of crystallization optimization and screened 134 crystals at synchrotron beam lines. The 
best crystal diffracted at 3.6-Ǻ resolution, which allowed us to determine the structure of 
the N-terminal fragment of USP11. Alignment of the USP11 DUSP-UBL with USP4 
DUSP-UBL shows that the tertiary structure of these domains is similar. Unfortunately, 
we could not assign the amino acid residues in the DU finger that links these two domains 
due to the relatively low resolution of our structure. Our laboratory is currently carrying 
out experiments to express full length USP11 in insect cells. If USP11 expression is high 
and the purified protein is intact, we could use the full length protein to form crystals and 
solve the structure.     
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Appendixes  
 
Supplementary Table S1. List of plasmid constructs designed for use in yeast two-hybrid 
screening. Target DNA was cut from the original plasmids and pasted into pGADT7M, 
modified version of pGADT7 with multiple cloning sites (Dr. G. Maertens, unpublished 
results). 
  
 
 
Supplementary Table S2. List of primers designed for plasmid constructs used for in vitro 
pull down studies. The verified PCR products were cloned into pGEX-6P-3, pGEX-6P-1 
(GE Healthcare) or pET28a-SUMO (kindly provided by Andre LB Ambrosio, Laboratório 
Nacional de Biociências - LNBio, CNPEM, Brazil). 
 
Plasmids   Restriction 
Digestion 
Template Primer (sense) Primer (anti-sense) 
pGEX-6p-3- BMI1/1-
109 
BamH1  
XhoI 
pQBMI1-Flag 
 (Maertens et al, 2009) 
CCGGCAATTGAT
GCATCGAACAAC
GAGAATC 
CCGGCTCGAGTCAGC
CATTGGCAGCATCAG
C  
pGEX-6p-3-BMI1/1-
300 
BamH1  
SalI 
pQBMI1-Flag  
(Maertens et al, 2009)  
CCGGCAATTGAT
GCATCGAACAAC
GAGAATC 
CTGAGTCGACTCAGG
GGCTGTTGCTGG 
pCFD-H6P-Duet1-
BMI1 
BglI  
XhoI 
pQBMI1-Flag  
 (Maertens et al, 2009) 
CCGGCAATTGAT
GCATCGAACAAC
GAGAATC 
CCGGCTCGAGTCAAC
CAGAAGAAGTTGCT
GATGACC 
pGEX-6p-3-
RING2/1-331 
BamH1  
XhoI 
pGM-Flag-RING2 
(Maertens et al, 2010)  
CCGGGGATCCAT
GTCTCAGGCTGT
GCAGACAAACGG 
CCGGCTCGAGTCAAG
GTGCGTAATAAAGTT
CCATGG 
pGEX-6p-3-
RING2/1-159 
BamH1  
XhoI 
pGM-Flag-RING2 
(Maertens et al, 2010)  
CCGGGGATCCAT
GTCTCAGGCTGT
GCAGACAAACGG 
CCGGCTCGAGTCAGC
CTCGCTGCAGTCTGT
TC  
pGEX-6p-1- RYBP  SalI  
EcoR1 
Hela cDNA Library  GGCCGAATTCAT
GACCATGGGCGA
CAAGAAG 
CCGGGTCGACTCAGA
AAGATTCATCATTGA
CTGCTG  
Plasmids  Construct Restriction 
Digestion 
Original plasmid  
pGADT7M-USP11/ΔDUSP AgeI  / EcoR1 pQHA- USP11/ΔDUSP 
pGADT7M-USP11/ΔDUSP ΔDUF AgeI  / EcoR1 pQHA-USP11/ΔDUSP ΔDUF 
pGADT7M-USP11/ΔUCH1 AgeI  / EcoR1 pQHA-USP11/ΔUCH1 
pGADT7M-USP11/ΔUCH2 AgeI  / EcoR1 pQHA-USP11/ΔUCH2 
pGADT7M-USP11/ΔUCH1&UCH2 AgeI  / EcoR1 pQHA-USP11/ΔUCH1&UCH2 
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Supplementary Table S3. List of primers designed for plasmid constructs used for in vitro 
pull down studies. Target DNS was cut from the original plasmids with appropriate 
restriction digestion enzymes. .  
 
 
 
 
Supplementary Table S4. List of primers designed for plasmid constructs used to express 
USP11 fragments. The verified PCR products were cloned into pCDF-H6P-PP2ACA 
(Maertens G. unpublished results).  
 
Plasmids Restriction 
Digestion 
Template Primer (sense) Primer (anti-
sense) 
pCDF-H6P-Duet1-
USP11/1-286 
SalI   
EcoR1 
pQHA-USP11wt 
(Maertens et al, 2010) 
GGCCGAATTCATG
GCAGTAGCCCCGC
G 
GGCCGTCGACTCA
TGCGCTGGGCCAA
GTGCC 
pCDF-H6P-Duet1-
USP11/76-286 
SalI   
EcoR1 
pQHA-USP11wt 
(Maertens et al, 2010) 
GGCCGAATTCCCA
GGCCTGGACAGCC 
GGCCGTCGACTCA
TGCGCTGGGCCAA
GTGCC 
pCDF-H6P-Duet1-
USP11/76-
286[E106AK107A] 
SalI   
EcoR1 
pCDF-H6P-Duet1-
USP11/76-286 
CGAAAGCTGGTTC
CTTGTGGCGGCGC
ACTGGTATAAGCA
GTGG 
CCACTGCTTATACC
AGTGCGCCGCCAC
AAGGAACCAGCTT
TCG 
pCDF-H6P-Duet1-
USP11/76-
286[K146AE147A] 
SalI   
EcoR1 
pCDF-H6P-Duet1-
USP11/76-286 
GAGATAAACTGGC
GCCTCGCGGCGGG
ACTGGTGGAAGGC
GAGG 
CCTCGCCTTCCACC
AGTCCCGCCGCGA
GGCGCCAGTTTATC
TC 
pCDF-H6P-Duet1-
USP11/76-
286[K278AK279A] 
SalI   
EcoR1 
pCDF-H6P-Duet1-
USP11/76-286 
GATCATCATGGAG
ACCCGCGCGGCAG
ATGGCACTTGGCC
CAGC 
GCTGGGCCAAGTG
CCATCTGCCGCGCG
GGTCTCCATGATG
ATC 
 
Plasmids   Restriction 
Digestion 
Original Plasmid  
pET-28a-SUMO-BMI1/1-300 BamH1 / SalI pGEX-6p-3-BMI1/1-300 
pET-28a-SUMO-BMI1  BamH1 / XhoI pGEX-6p-3-BMI1 
pET-28a-SUMO-RING2/1-331 BamH1 / XhoI pGEX-6p-3-RING2/1-331 
pCDF-H6P-RYBP/BMI1 BamH1 / XhoI pCDF-H6P-RYBP 
pCDF-H6P-Duet1-BMI1 
